Acoustic Neuroma

Neoplastic MONDO:0001569 Pathograph 18 Show in embeddings browser schwannoma

Acoustic neuroma, anatomically termed vestibular schwannoma, is a benign Schwann-cell tumor arising from a vestibular division of cranial nerve VIII. Most tumors are sporadic and unilateral, whereas bilateral vestibular schwannomas are a hallmark of NF2-related schwannomatosis. The core tumor mechanism is biallelic NF2 inactivation with merlin loss, followed by loss of contact-dependent growth restraint and YAP/TAZ-TEAD-dependent proliferative signaling. Hearing and balance morbidity can reflect both local eighth-nerve effects and cochlear injury; larger cerebellopontine-angle tumors can affect adjacent cranial nerves and the brainstem.

Ask OpenScientist

Ask a research question about Acoustic Neuroma. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Definitions
7
Pathophys.
4
Phenotypes
3
Gaps
18
Pathograph
2
Genes
4
Medical Actions
2
Subtypes
3
Models
17
References
1
Deep Research
📘

Definitions

1
Vestibular schwannoma disease definition
A benign tumor formed by neoplastic Schwann cells on the eighth cranial nerve, usually arising from a vestibular nerve division.
OTHER Lesion-level definition; NF2-related schwannomatosis remains a separate tumor-predisposition syndrome.
Show evidence (1 reference)
PMID:38892775 SUPPORT Human Clinical
"Vestibular schwannoma (VS) is a benign tumor of the eighth cranial nerve formed from neoplastic Schwann cells."
The review provides a concise lesion-level definition.
◆

Subtypes

2
Sporadic Unilateral Vestibular Schwannoma
The usual presentation is a unilateral sporadic tumor with somatic NF2 inactivation in tumor tissue and no inherited NF2 syndrome.
Show evidence (1 reference)
PMID:28710469 SUPPORT Human Clinical
"The vast majority (95%) of VSs are unilateral and sporadic schwannomas, which occur predominantly in the 4th to 6th decades of life"
This human tumor study distinguishes the predominant unilateral sporadic context.
?

Discussions and Knowledge Gaps

3
How faithfully do Nf2-null mouse tumors, isolated human primary cells, and murine cochlear explants reproduce the human eighth-nerve anatomy, immune and vascular microenvironment, hearing loss, tinnitus, and vestibular natural history of sporadic vestibular schwannoma?
HUMAN MODEL MISMATCH OPEN mismatch_acoustic_preclinical_models_and_human_function
Attached to
pathophysiology#YAP/TAZ-TEAD-Dependent Mitogenic Signaling pathophysiology#Vestibular Schwannoma Secretome and Cochlear Injury
The YAP/TAZ study establishes tumor-growth dependence in primary cells and mouse models, but not human auditory outcomes. The secretome experiment applies human tumor products to murine cochlear explants, establishing plausibility but not the in-vivo fraction of human hearing loss caused by soluble factors. A human multicellular model preserving tumor, nerve, cochlear, immune, and vascular interactions is needed to bridge these gaps.
Proposed experiments
Patient-derived vestibular schwannoma, auditory-neuron, and cochlear co-culture
human multicellular tumor-neural co-culture perturbation assay Relation: this experiment is of type this experiment type This experiment is of type human multicellular tumor-neural co-culture perturbation assay.
exp_acoustic_human_tumor_nerve_cochlea_coculture
Compare patient-derived NF2-null tumor cells and isogenic NF2-restored controls in a human multicellular co-culture containing auditory neurons and cochlear sensory cells; perturb TEAD and neutralize candidate secreted factors while measuring tumor growth, neurite integrity, hair-cell survival, and electrophysiologic function.
Model systems
Human vestibular schwannoma-auditory pathway co-culture
Human patient-derived tumor cells combined with auditory-neural and cochlear sensory-cell compartments.
CO CULTURE
human NCBITaxon:9606 NCBI Taxonomy (NCBITaxon) Relation: this experimental model is built in this organism This experimental model is built in human, annotated with Homo sapiens (NCBITaxon:9606). NCBITaxon:9606 is an organism from the NCBI Taxonomy.
Show evidence (2 references)
PMID:36148553 SUPPORT Model Organism
"successful use of TEAD palmitoylation inhibitors in a preclinical mouse model of schwannoma points to their potential future clinical use."
The explicitly preclinical framing motivates a human translational bridge.
PMID:26690506 SUPPORT In Vitro
"murine cochlear explant cultures were treated with human tumour secretions from thirteen different unilateral, sporadic VSs"
The cross-species design defines the fidelity question for cochlear injury.
What proportions of vestibular-schwannoma-associated hearing loss arise from retrocochlear nerve effects, mechanical compression, cochlear degeneration, or tumor-secreted factors, and why can hearing severity diverge from tumor size?
INTERPRETATION OPEN interpretation_acoustic_hearing_not_size_only
Attached to
pathophysiology#Vestibular Schwannoma Formation and Tumor Growth pathophysiology#Vestibular Schwannoma Secretome and Cochlear Injury
Human temporal-bone data show cochlear degeneration, while tumor size and distance from the cochlea did not correlate with structural cochlear change or hearing threshold. A compression-only graph would therefore overstate what is known; the entry retains parallel local-nerve and secretome/cochlear branches.
Show evidence (1 reference)
PMID:22377650 SUPPORT Human Clinical
"Tumor size, distance from the cochlea, and nerve of origin did not correlate with structural changes in the cochlea or the hearing threshold."
Human pathology supports a mechanism more complex than tumor size or proximity alone.
How should observation, radiosurgery, fractionated radiotherapy, and microsurgery be compared when tumor size, symptoms, hearing, age, and other selection factors differ across mostly nonrandomized studies?
INTERPRETATION OPEN interpretation_acoustic_treatment_comparisons
Attached to
treatments#Observation with Serial MRI and Audiometry treatments#Microsurgical Resection treatments#Stereotactic Radiosurgery or Fractionated Radiotherapy
Guidelines emphasize individualized selection and explicitly characterize the evidence base as low. Network rankings are heavily influenced by observational cohorts and should not be read as causal head-to-head superiority for every patient.
Show evidence (2 references)
PMID:31504802 SUPPORT Human Clinical
"The level of evidence to provide treatment recommendations for vestibular schwannoma is low compared with other intracranial neoplasms."
EANO explicitly identifies the limited comparative evidence base.
PMID:39627752 SUPPORT Human Clinical
"34 non-RCTs and 1 RCT that included 6 interventions were analyzed."
The network meta-analysis is overwhelmingly based on nonrandomized studies.
⚙

Pathophysiology

7
Biallelic NF2 Inactivation and Merlin Loss
In the predominant sporadic form, pathogenic NF2 alterations and/or loss of the second NF2 allele occur in tumor tissue and eliminate merlin tumor-suppressor activity. Germline NF2 predisposition followed by a somatic second hit produces the analogous lesion in NF2-related tumors.
Schwann cell CL:0002573 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Schwann cell (CL:0002573). CL:0002573 is a cell type from the Cell Ontology.
NF2 hgnc:7773 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves NF2 (hgnc:7773). hgnc:7773 is a gene from the HUGO Gene Nomenclature Committee.
Downstream
Loss of Merlin-Dependent Contact Inhibition and Receptor Control Merlin loss removes contact-dependent restriction of growth-factor receptor delivery and mitogenic signaling in Schwann cells.
YAP/TAZ-TEAD-Dependent Mitogenic Signaling NF2-null schwannoma cells acquire dependence on YAP/TAZ-driven TEAD transcriptional output through the Hippo pathway.
Show evidence (3 references)
PMID:39941762 SUPPORT Human Clinical
"Biallelic NF2 inactivation primarily drives vestibular schwannoma tumorigenesis."
Paired lymphocyte and tumor-DNA analysis directly supports biallelic NF2 inactivation in both sporadic unilateral and NF2-related tumors.
PMID:40295009 SUPPORT Human Clinical
"Pathogenic variants and allele-loss of the NF2 gene with Merlin loss as consequence is the driving genetic event for vestibular schwannoma development."
Sequencing of sporadic tumors identifies NF2 alteration or allele loss as the principal genetic event.
PMID:28710469 SUPPORT Human Clinical
"The great majority of sporadic vestibular schwannomas (VSs) are due to the inactivation of the NF2 gene."
Human sporadic-tumor data support NF2 inactivation as the upstream lesion.
Loss of Merlin-Dependent Contact Inhibition and Receptor Control
Merlin normally limits delivery of growth-factor receptors to the Schwann-cell surface at cell-cell contact and restrains downstream AKT and MAPK signaling. Merlin loss weakens contact inhibition and permits excess mitogenic receptor signaling.
Schwann cell CL:0002573 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Schwann cell (CL:0002573). CL:0002573 is a cell type from the Cell Ontology.
contact inhibition GO:0060242 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased contact inhibition (GO:0060242). GO:0060242 is a biological process from the Gene Ontology. ↓ DECREASED
Downstream
Vestibular Schwannoma Formation and Tumor Growth Loss of contact-dependent restraint permits neoplastic Schwann-cell proliferation.
Show evidence (1 reference)
PMID:19029950 SUPPORT In Vitro
"merlin regulates contact inhibition of proliferation by limiting the delivery of several growth factor receptors at the plasma membrane of primary SCs."
Primary Schwann-cell experiments directly define merlin's contact-dependent receptor-control function.
YAP/TAZ-TEAD-Dependent Mitogenic Signaling
NF2-null schwannoma cells depend on YAP/TAZ-driven TEAD transcriptional activity. Genetic YAP/TAZ ablation or pharmacologic TEAD inhibition blocks and can regress schwannoma growth in primary-cell and mouse models, making this a preclinical rather than approved clinical target.
Schwann cell CL:0002573 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Schwann cell (CL:0002573). CL:0002573 is a cell type from the Cell Ontology.
positive regulation of Schwann cell proliferation GO:0010625 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased positive regulation of Schwann cell proliferation (GO:0010625). GO:0010625 is a biological process from the Gene Ontology. ↑ INCREASED
Experimental models
Human primary schwannoma-cell model PRIMARY CELL CULTURE Genetic and pharmacologic perturbations test YAP/TAZ-TEAD dependence.
Downstream
Vestibular Schwannoma Formation and Tumor Growth YAP/TAZ-driven TEAD transcription sustains NF2-null schwannoma growth.
Show evidence (2 references)
PMID:36148553 SUPPORT In Vitro
"Hippo signalling may be successfully targeted in vitro"
In-vitro perturbation directly supports YAP/TAZ-TEAD dependence in schwannoma cells.
PMID:36148553 SUPPORT Model Organism
"successful use of TEAD palmitoylation inhibitors in a preclinical mouse model of schwannoma points to their potential future clinical use."
A preclinical mouse model independently supports in-vivo targetability of TEAD activity.
Vestibular Schwannoma Formation and Tumor Growth
Proliferating neoplastic Schwann cells form a benign tumor on a vestibular division of cranial nerve VIII. Tumors may remain intrameatal or extend into the cerebellopontine angle; growth rate and clinical effects vary widely.
Schwann cell CL:0002573 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Schwann cell (CL:0002573). CL:0002573 is a cell type from the Cell Ontology.
positive regulation of Schwann cell proliferation GO:0010625 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased positive regulation of Schwann cell proliferation (GO:0010625). GO:0010625 is a biological process from the Gene Ontology. ↑ INCREASED
vestibulocochlear nerve UBERON:0001648 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in vestibulocochlear nerve (UBERON:0001648). UBERON:0001648 is an anatomical location from the Uberon multi-species anatomy ontology. internal acoustic meatus UBERON:0011859 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in internal acoustic meatus (UBERON:0011859). UBERON:0011859 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Vestibular Schwannoma Secretome and Cochlear Injury Tumor-derived soluble factors can damage cochlear hair cells and neurites independently of a simple compression-only model.
Eighth-Nerve Auditory and Vestibular Dysfunction Tumor involvement of cranial nerve VIII disrupts auditory and vestibular function.
Cerebellopontine-Angle Expansion and Advanced Mass Effect Extrameatal growth can compress adjacent cranial nerves and the brainstem.
Show evidence (1 reference)
PMID:28710469 SUPPORT In Vitro
"Following the loss of NF2 expression, schwannoma cultures demonstrated increased proliferation rates."
NF2 loss increases proliferation in human sporadic schwannoma cultures.
Vestibular Schwannoma Secretome and Cochlear Injury
Soluble factors released by vestibular schwannomas can injure cochlear hair cells and neuronal fibers. Human temporal-bone pathology corroborates ipsilateral cochlear degeneration, although the relative contributions of secreted factors and retrocochlear injury remain uncertain.
cochlea UBERON:0001844 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in cochlea (UBERON:0001844). UBERON:0001844 is an anatomical location from the Uberon multi-species anatomy ontology.
Experimental models
Human vestibular-schwannoma secretions on murine cochlear explants OTHER The cross-species explant assay tests whether soluble human tumor products can injure cochlear cells.
Downstream
Sensorineural Hearing Impairment Cochlear hair-cell and neuronal degeneration contributes to sensorineural hearing loss.
Show evidence (2 references)
PMID:26690506 SUPPORT In Vitro
"Secretions from tumours associated with most substantial SNHL resulted in most significant hair cell loss and neuronal fibre disorganization."
Conditioned-media experiments link human tumor secretions to cochlear cellular injury.
PMID:22377650 SUPPORT Human Clinical
"VS caused significantly more inner and outer hair cell loss, cochlear neuronal loss, precipitate in endolymph and perilymph, and decreased pure tone average, when compared with the opposite ear."
Human temporal-bone histology corroborates ipsilateral cochlear degeneration.
Eighth-Nerve Auditory and Vestibular Dysfunction
Vestibular schwannoma disrupts cranial-nerve VIII function, producing auditory symptoms and objective dysfunction of superior and inferior vestibular divisions. Central compensation helps explain why objective vestibular deficits and perceived vertigo do not always align.
vestibulocochlear nerve UBERON:0001648 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in vestibulocochlear nerve (UBERON:0001648). UBERON:0001648 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Sensorineural Hearing Impairment Retrocochlear auditory-nerve dysfunction is one contributor to sensorineural hearing impairment, alongside the parallel cochlear-injury branch.
Tinnitus Vestibular schwannoma-associated auditory-pathway dysfunction can present with tinnitus, but the exact causal intermediary is unresolved.
Abnormal Vestibular Function Superior and inferior vestibular nerve dysfunction produces abnormal vestibular testing and may manifest as disequilibrium or vertigo.
Show evidence (1 reference)
PMID:25794859 SUPPORT Human Clinical
"Our results indicate that dysfunction of the superior and inferior vestibular nerve evolves in parallel for most patients with schwannoma."
Objective human testing documents dysfunction of both vestibular nerve divisions.
Cerebellopontine-Angle Expansion and Advanced Mass Effect
Larger extrameatal tumors can compress the brainstem and adjacent cranial nerves in the cerebellopontine angle. Trigeminal manifestations are a conditional advanced-tumor effect, not a universal feature.
cerebellopontine angle UBERON:0014908 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in cerebellopontine angle (UBERON:0014908). UBERON:0014908 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Trigeminal Sensory Disturbance Large tumors can produce trigeminal sensory symptoms through local mass effect.
Show evidence (1 reference)
PMID:8971818 SUPPORT Human Clinical
"Key symptoms of various tumor extension classes precipitated the diagnosis, such as trigeminal disturbances in large tumors with brain stem compression or tinnitus in small neuromas."
A 1,000-patient clinical series associates large tumors and brainstem compression with trigeminal symptoms without proving every local mass-effect step.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Acoustic Neuroma Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

4
Ear 2
Sensorineural Hearing Impairment HP:0000407 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Sensorineural hearing impairment (HP:0000407). HP:0000407 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:22377650 SUPPORT Human Clinical
"Hearing loss is a common symptom in patients with cochleovestibular schwannoma."
Human clinicopathologic data directly support hearing loss as a common manifestation.
Tinnitus HP:0000360 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Tinnitus (HP:0000360). HP:0000360 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:38892775 SUPPORT Human Clinical
"Although VS can cause a variety of symptoms, tinnitus is one of the most distressing symptoms for patients and can greatly impact quality of life."
The systematic review supports tinnitus as a clinically important manifestation.
Other 2
Abnormal Vestibular Function HP:0001751 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Abnormal vestibular function (HP:0001751). HP:0001751 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:25794859 SUPPORT Human Clinical
"Unexplained vHIT and VEMP asymmetry should alert otologists and neurologists to undertake imaging in patients presenting with non-specific disequilibrium or vertigo."
Objective vestibular testing and associated disequilibrium/vertigo support the broad vestibular phenotype.
Trigeminal Sensory Disturbance
Show evidence (1 reference)
PMID:8971818 SUPPORT Human Clinical
"Key symptoms of various tumor extension classes precipitated the diagnosis, such as trigeminal disturbances in large tumors with brain stem compression or tinnitus in small neuromas."
This directly supports trigeminal symptoms as a large-tumor presentation.
🧬

Genetic Associations

2
Somatic NF2 inactivation in sporadic vestibular schwannoma (Somatic NF2 pathogenic variants and allele loss drive the predominant sporadic tumor context.)
Gene: NF2 hgnc:7773 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is NF2 (hgnc:7773). hgnc:7773 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: SOMATIC_DRIVER variant_origin: SOMATIC
Show evidence (3 references)
PMID:39941762 SUPPORT Human Clinical
"patients with uVS often exhibit one NF2 variant with LOH."
Paired tumor and lymphocyte analysis supports somatic two-hit NF2 inactivation in unilateral vestibular schwannoma.
PMID:40295009 SUPPORT Human Clinical
"Among the 41 tumor samples, 34 had one pathogenic variant or an allele-loss of NF2 gene and one tumor showed a pathogenic variant in the LZTR1 gene."
Tumor sequencing demonstrates frequent somatic NF2 alteration or allele loss in sporadic vestibular schwannoma.
PMID:40295009 SUPPORT Human Clinical
"none of these variants was found in blood."
Absence from blood supports a somatic rather than inherited origin in this cohort.
💊

Medical Actions

4
Observation with Serial MRI and Audiometry
Category: Monitoring Action: observationNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is observation, annotated with Observation Activity (NCIT:C25598). NCIT:C25598 is a clinical intervention from the NCI Thesaurus. Ontology label: Observation Activity NCIT:C25598
Observation is appropriate for selected patients based on tumor size, symptoms, hearing, documented growth, age, comorbidity, and preference. Limited initial growth does not invariably require immediate intervention.
Show evidence (2 references)
PMID:31504802 SUPPORT Human Clinical
"Current treatment options include observation, surgical resection, fractionated radiotherapy, and radiosurgery."
EANO recognizes observation as a core management option.
PMID:34121081 SUPPORT Human Clinical
"Because early treatment does not confer improved long-term quality of life outcomes, toleration of some growth during observation is justifiable in appropriately selected cases."
Cohort evidence supports continued surveillance in carefully selected patients.
Microsurgical Resection
Category: Therapeutic Action: surgical procedureNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is surgical procedure (NCIT:C15329). NCIT:C15329 is a clinical intervention from the NCI Thesaurus. Ontology label: Surgical Procedure NCIT:C15329
Microsurgery removes or decompresses tumor when size, mass effect, progression, symptoms, hearing goals, or patient factors favor operative treatment. Approach and extent must balance tumor control against hearing and facial-nerve morbidity.
Mechanism Target:
INHIBITS Cerebellopontine-Angle Expansion and Advanced Mass Effect — Resection removes or decompresses advanced local tumor burden; INHIBITS is the closest available treatment-effect category for that reduction.
Show evidence (1 reference)
PMID:31504802 SUPPORT Human Clinical
"In small tumors, observation has to be weighed against radiosurgery, in large tumors surgical decompression is mandatory, potentially followed by fractionated radiotherapy or radiosurgery."
The guideline directly supports surgical decompression as the tumor-burden intervention for large lesions.
Show evidence (1 reference)
PMID:40470965 SUPPORT Human Clinical
"Surgical intervention remains an important option in the management of vestibular schwannoma (VSs)."
The updated CNS guideline supports surgery as a central management option.
Stereotactic Radiosurgery or Fractionated Radiotherapy
Category: Therapeutic Action: radiation therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is radiation therapy (NCIT:C15313). NCIT:C15313 is a clinical intervention from the NCI Thesaurus. Ontology label: Radiation Therapy NCIT:C15313
Radiation-based local therapy is selected according to tumor size, location, symptoms, prior treatment, and patient factors. Comparative estimates are dominated by nonrandomized studies and should not be read as universal superiority over observation or surgery.
Mechanism Target:
INHIBITS Vestibular Schwannoma Formation and Tumor Growth — Radiosurgery or fractionated radiotherapy aims for local tumor control rather than direct pathway-specific YAP/TAZ inhibition.
Show evidence (1 reference)
PMID:39627752 SUPPORT Human Clinical
"We found the MS, and different SRS all had better tumor local control rates."
The network meta-analysis supports local tumor control, with partial support because almost all included studies were nonrandomized.
Show evidence (1 reference)
PMID:31504802 SUPPORT Human Clinical
"Current treatment options include observation, surgical resection, fractionated radiotherapy, and radiosurgery."
EANO recognizes both fractionated radiotherapy and radiosurgery as core options.
🔬

Diagnosis

2
Magnetic resonance imaging
MRI establishes the radiologic diagnosis, characterizes intrameatal and cerebellopontine-angle extent, and provides the baseline for subsequent growth surveillance. Histologic verification is not always required.
magnetic resonance imaging procedure NCIT:C16809 NCI Thesaurus (NCIT)
Results: MRI demonstrates a lesion compatible with vestibular schwannoma on cranial nerve VIII.
Show evidence (1 reference)
PMID:31504802 SUPPORT Human Clinical
"The radiological diagnosis of vestibular schwannoma is made by magnetic resonance imaging. Histological verification of the diagnosis is not always required."
The guideline directly supports MRI-based diagnosis without mandatory tissue confirmation.
Audiologic assessment
Pure-tone and speech audiometry characterize asymmetric hearing loss and provide a functional baseline. Audiologic symptoms prompt MRI screening but are not specific for vestibular schwannoma.
hearing examination NCIT:C38036 NCI Thesaurus (NCIT)
Results: Quantifies hearing thresholds and speech discrimination and identifies asymmetric or unilateral sensorineural hearing loss.
Show evidence (2 references)
PMID:40470968 SUPPORT Human Clinical
"We aim to assess the diagnostic yield of MRI in the detection of VS in patients presenting with asymmetric sensorineural hearing loss (SNHL), unilateral tinnitus, and sudden SNHL."
The current CNS guideline connects audiologic presentations to diagnostic MRI screening for vestibular schwannoma.
PMID:19587327 SUPPORT Human Clinical
"Hearing response was monitored with the use of serial audiologic evaluations, including determination of pure-tone thresholds and word-recognition scores"
A vestibular-schwannoma clinical study directly documents the pure-tone and word-recognition measures named in this assessment.
🩻

Imaging Findings

1
Vestibular schwannoma visible on MRI
Mri Diagnostic
Vestibular schwannoma HP:0009588 Human Phenotype Ontology (HP) vestibulocochlear nerve UBERON:0001648 Uberon multi-species anatomy ontology (UBERON) Vestibular schwannoma HP:0009588 Human Phenotype Ontology (HP)
MRI defines the radiologic diagnosis. The lesion arises on a vestibular division of cranial nerve VIII and may extend from the internal acoustic meatus into the cerebellopontine angle.
Show evidence (2 references)
PMID:31504802 SUPPORT Human Clinical
"The radiological diagnosis of vestibular schwannoma is made by magnetic resonance imaging."
The EANO guideline identifies MRI as the radiologic diagnostic method.
PMID:28710469 SUPPORT Human Clinical
"Vestibular schwannomas (VSs) are benign tumours that originate from myelin-forming schwann cells that surround the vestibular branches of the 8th (auditory) cranial nerve."
Human tumor data supply the anatomic origin represented by the imaging finding.
📈

Progression

1
Variable growth during imaging observation
Sporadic Unilateral
Growth is not uniform. In a prospective national cohort, most detected growth occurred in the first five years, and extrameatal tumors grew more often than intrameatal tumors. Continued observation can remain reasonable in selected patients, even after limited initial growth.
Show evidence (2 references)
PMID:33068429 SUPPORT Human Clinical
"5 years after diagnosis, 21% of the intrameatal tumors exhibited growth during observation, whereas 37% of extrameatal tumors had grown, increasing to 25% intrameatal and 42% extrameatal after 10 years."
Prospective national data quantify the variable natural history by tumor location.
PMID:34121081 SUPPORT Human Clinical
"Growth detected during observation does not necessarily portend future growth, especially for slowly growing tumors."
This multi-institutional cohort supports individualized surveillance rather than assuming continuous growth.
📊

Prevalence

2
Modern population-based studies in Denmark, the Netherlands, Taiwan, and the United States
Annual Incidence 3.0–5.2 per 100,000 1–9 per 100,000 Sporadic Unilateral
Range of recent all-age incidence estimates for sporadic vestibular schwannoma.
Show evidence (1 reference)
PMID:34464224 SUPPORT Human Clinical
"Most recent incidence rates of among all ages ranged between 3.0 and 5.2 per 100,000 person-years."
The systematic review reports a modern international annual-incidence range.
Olmsted County, Minnesota residents on January 1, 2017
Point Prevalence 42.0 per 100,000 1–9 per 10,000 Sporadic Unilateral
Point prevalence of confirmed sporadic vestibular schwannoma in a population-linked medical-record cohort.
Show evidence (1 reference)
PMID:30688755 SUPPORT Human Clinical
"Sixty-seven persons from a population of nearly 160,000 were living with VS on January 1, 2017, resulting in a point prevalence of 42.0 per 100,000 persons."
The population-based cohort supplies the date-specific point-prevalence estimate.
🧫

Experimental Models

2
Human primary schwannoma-cell model PRIMARY_CELL_CULTURE
Human primary schwannoma cells are used to examine YAP/TAZ-TEAD activity and its response to genetic or pharmacologic perturbation.
Human primary schwannoma cells YAP/TAZ genetic or TEAD pharmacologic perturbation
Schwann cell CL:0002573 Cell Ontology (CL) Relation: this experimental model uses this cell type This experimental model uses Schwann cell (CL:0002573). CL:0002573 is a cell type from the Cell Ontology.
Organism
human NCBITaxon:9606 NCBI Taxonomy (NCBITaxon) Relation: this experimental model is built in this organism This experimental model is built in human, annotated with Homo sapiens (NCBITaxon:9606). NCBITaxon:9606 is an organism from the NCBI Taxonomy.
Cell source
Human primary schwannoma tumor cells
Pathograph links
YAP/TAZ-TEAD-Dependent Mitogenic Signaling Genetic and pharmacologic perturbations test YAP/TAZ-TEAD dependence.
Show evidence (1 reference)
PMID:36148553 SUPPORT In Vitro
"Hippo signalling may be successfully targeted in vitro"
The in-vitro result directly supports use of the primary-cell system to interrogate YAP/TAZ-TEAD dependence.
Findings
ALDH1A1 is a TAZ-driven Hippo-signaling target in human NF2-null schwannoma cells.
"The study identifies a TAZ-linked cellular target in human NF2-null schwannoma cells, with parallel mouse-cell confirmation."
Show evidence (1 reference)
PMID:36148553 SUPPORT In Vitro
"driven by the TAZ protein in human and mouse NF2-null schwannoma cells"
This cellular finding directly supports the human NF2-null schwannoma-cell component while also reporting mouse-cell confirmation.
Show evidence (1 reference)
PMID:36148553 SUPPORT In Vitro
"Using a combination of human primary tumour cells"
This directly identifies the human primary-cell component of the model.
Human vestibular-schwannoma secretions on murine cochlear explants OTHER
Conditioned media from resected human unilateral sporadic vestibular schwannomas are applied to murine cochlear explants to test tumor-secreted injury to hair cells and neuronal fibers.
Human vestibular schwannoma-conditioned medium
Organism
house mouse NCBITaxon:10090 NCBI Taxonomy (NCBITaxon) Relation: this experimental model is built in this organism This experimental model is built in house mouse, annotated with Mus musculus (NCBITaxon:10090). NCBITaxon:10090 is an organism from the NCBI Taxonomy.
Cell source
Neonatal murine cochlear explants exposed to secretions from human tumors
Pathograph links
Vestibular Schwannoma Secretome and Cochlear Injury The cross-species explant assay tests whether soluble human tumor products can injure cochlear cells.
Show evidence (1 reference)
PMID:26690506 SUPPORT In Vitro
"murine cochlear explant cultures were treated with human tumour secretions from thirteen different unilateral, sporadic VSs of subjects demonstrating varied degrees of ipsilateral SNHL."
This sentence directly defines the model system and modeled mechanism.
Findings
Secretions from tumors associated with greater hearing loss produced greater cochlear hair-cell loss and neuronal-fiber disorganization.
"Cochlear explant damage roughly tracked the hearing loss of the patient whose tumor supplied the secretions."
Show evidence (1 reference)
PMID:26690506 SUPPORT In Vitro
"Secretions from tumours associated with most substantial SNHL resulted in most significant hair cell loss and neuronal fibre disorganization."
The conditioned-media experiment directly supports the model finding.
Show evidence (1 reference)
PMID:26690506 SUPPORT In Vitro
"Our results are the first to demonstrate that secreted factors from VSs can lead to cochlear damage."
The study supports the experimental model's central disease-mechanism claim.
🐁

Animal Models

1
Schwannoma mouse model used for YAP/TAZ-TEAD perturbation mouse Genetic and transplant schwannoma models
A preclinical mouse schwannoma model was used with YAP/TAZ-TEAD perturbation to test whether Hippo-effector activity is required for tumor growth.
Schwannoma tumor growth
Species
mouse
Genotype
Schwannoma mouse model used for YAP/TAZ-TEAD perturbation
Genes
NF2 hgnc:7773 HUGO Gene Nomenclature Committee (hgnc) Relation: this experimental model concerns this gene This experimental model concerns NF2 (hgnc:7773). hgnc:7773 is a gene from the HUGO Gene Nomenclature Committee.
Show evidence (1 reference)
PMID:36148553 SUPPORT Model Organism
"successful use of TEAD palmitoylation inhibitors in a preclinical mouse model of schwannoma points to their potential future clinical use."
The abstract directly documents an in-vivo mouse schwannoma treatment model without requiring an unsupported strain-level genotype.
{ }

Source YAML

click to show 
name: Acoustic Neuroma
creation_date: '2026-05-10T15:02:10Z'
category: Neoplastic
categories:
- Benign Neoplasm
- Peripheral Nerve Sheath Tumor
- Cranial Nerve Tumor
parents:
- schwannoma
synonyms:
- vestibular schwannoma
- acoustic schwannoma
- acoustic neurinoma
- acoustic neurilemmoma
- vestibular neurilemmoma
disease_term:
  preferred_term: acoustic neuroma
  term:
    id: MONDO:0001569
    label: acoustic neuroma
description: >-
  Acoustic neuroma, anatomically termed vestibular schwannoma, is a benign
  Schwann-cell tumor arising from a vestibular division of cranial nerve VIII.
  Most tumors are sporadic and unilateral, whereas bilateral vestibular
  schwannomas are a hallmark of NF2-related schwannomatosis. The core tumor
  mechanism is biallelic NF2 inactivation with merlin loss, followed by loss of
  contact-dependent growth restraint and YAP/TAZ-TEAD-dependent proliferative
  signaling. Hearing and balance morbidity can reflect both local
  eighth-nerve effects and cochlear injury; larger cerebellopontine-angle tumors
  can affect adjacent cranial nerves and the brainstem.
definitions:
- name: Vestibular schwannoma disease definition
  definition_type: OTHER
  description: >-
    A benign tumor formed by neoplastic Schwann cells on the eighth cranial
    nerve, usually arising from a vestibular nerve division.
  scope: Lesion-level definition; NF2-related schwannomatosis remains a separate tumor-predisposition syndrome.
  evidence:
  - reference: PMID:38892775
    reference_title: "Vestibular Schwannoma and Tinnitus: A Systematic Review of Microsurgery Compared to Gamma Knife Radiosurgery."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Vestibular schwannoma (VS) is a benign tumor of the eighth cranial nerve formed from neoplastic Schwann cells."
    explanation: The review provides a concise lesion-level definition.
has_subtypes:
- name: Sporadic Unilateral
  display_name: Sporadic Unilateral Vestibular Schwannoma
  classification: etiologic_context
  description: >-
    The usual presentation is a unilateral sporadic tumor with somatic NF2
    inactivation in tumor tissue and no inherited NF2 syndrome.
  evidence:
  - reference: PMID:28710469
    reference_title: Differential NF2 Gene Status in Sporadic Vestibular Schwannomas and its Prognostic Impact on Tumour Growth Patterns.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The vast majority (95%) of VSs are unilateral and sporadic schwannomas, which occur predominantly in the 4th to 6th decades of life"
    explanation: This human tumor study distinguishes the predominant unilateral sporadic context.
- name: NF2-Related
  display_name: NF2-Related Vestibular Schwannoma
  classification: etiologic_context
  description: >-
    Vestibular schwannomas arising in NF2-related schwannomatosis are often
    bilateral and occur within a germline tumor-predisposition syndrome. This
    context does not make the syndrome itself a subtype of the tumor.
  evidence:
  - reference: PMID:20301380
    reference_title: NF2-Related Schwannomatosis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "NF2-related schwannomatosis (NF2) is characterized by bilateral vestibular schwannomas with associated symptoms of tinnitus, hearing loss, and balance dysfunction."
    explanation: GeneReviews identifies bilateral vestibular schwannomas as the defining NF2-related tumor context.
prevalence:
- subtype: Sporadic Unilateral
  population: Modern population-based studies in Denmark, the Netherlands, Taiwan, and the United States
  measure_type: ANNUAL_INCIDENCE
  prevalence_class: BAND_1_9_PER_100000
  rate_low: 3.0
  rate_high: 5.2
  notes: Range of recent all-age incidence estimates for sporadic vestibular schwannoma.
  evidence:
  - reference: PMID:34464224
    reference_title: "Global Incidence of Sporadic Vestibular Schwannoma: A Systematic Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Most recent incidence rates of among all ages ranged between 3.0 and 5.2 per 100,000 person-years."
    explanation: The systematic review reports a modern international annual-incidence range.
- subtype: Sporadic Unilateral
  population: Olmsted County, Minnesota residents on January 1, 2017
  measure_type: POINT_PREVALENCE
  prevalence_class: BAND_1_5_PER_10000
  rate_per_100000: 42.0
  notes: Point prevalence of confirmed sporadic vestibular schwannoma in a population-linked medical-record cohort.
  evidence:
  - reference: PMID:30688755
    reference_title: "Prevalence of Sporadic Vestibular Schwannoma: Reconciling Temporal Bone, Radiologic, and Population-based Studies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Sixty-seven persons from a population of nearly 160,000 were living with VS on January 1, 2017, resulting in a point prevalence of 42.0 per 100,000 persons."
    explanation: The population-based cohort supplies the date-specific point-prevalence estimate.
progression:
- phase: Variable growth during imaging observation
  subtype: Sporadic Unilateral
  notes: >-
    Growth is not uniform. In a prospective national cohort, most detected
    growth occurred in the first five years, and extrameatal tumors grew more
    often than intrameatal tumors. Continued observation can remain reasonable
    in selected patients, even after limited initial growth.
  evidence:
  - reference: PMID:33068429
    reference_title: The natural history of vestibular schwannoma growth-prospective 40-year data from an unselected national cohort.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      5 years after diagnosis, 21% of the intrameatal tumors exhibited growth
      during observation, whereas 37% of extrameatal tumors had grown,
      increasing to 25% intrameatal and 42% extrameatal after 10 years.
    explanation: Prospective national data quantify the variable natural history by tumor location.
  - reference: PMID:34121081
    reference_title: "Natural History of Growing Sporadic Vestibular Schwannomas During Observation: An International Multi-Institutional Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Growth detected during observation does not necessarily portend future growth, especially for slowly growing tumors."
    explanation: This multi-institutional cohort supports individualized surveillance rather than assuming continuous growth.
references:
- reference: PMID:31504802
  title: EANO guideline on the diagnosis and treatment of vestibular schwannoma.
- reference: PMID:34464224
  title: "Global Incidence of Sporadic Vestibular Schwannoma: A Systematic Review."
- reference: PMID:30688755
  title: "Prevalence of Sporadic Vestibular Schwannoma: Reconciling Temporal Bone, Radiologic, and Population-based Studies."
- reference: PMID:33068429
  title: The natural history of vestibular schwannoma growth-prospective 40-year data from an unselected national cohort.
- reference: PMID:28710469
  title: Differential NF2 Gene Status in Sporadic Vestibular Schwannomas and its Prognostic Impact on Tumour Growth Patterns.
- reference: PMID:40295009
  title: Pathogenic Variants and Allele Loss of the NF2 and LZTR1 Gene in Sporadic Vestibular Schwannoma.
- reference: PMID:39941762
  title: Genetic Alterations in Patients with NF2-Related Schwannomatosis and Sporadic Vestibular Schwannomas.
- reference: PMID:19029950
  title: Merlin regulates transmembrane receptor accumulation and signaling at the plasma membrane in primary mouse Schwann cells and in human schwannomas.
- reference: PMID:36148553
  title: Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.
- reference: PMID:26690506
  title: Secreted Factors from Human Vestibular Schwannomas Can Cause Cochlear Damage.
- reference: PMID:22377650
  title: "Dysfunction of the cochlea contributing to hearing loss in acoustic neuromas: an underappreciated entity."
- reference: PMID:25794859
  title: Prevalence of vestibular dysfunction in patients with vestibular schwannoma using video head-impulses and vestibular-evoked potentials.
- reference: PMID:8971818
  title: "Management of 1000 vestibular schwannomas (acoustic neuromas): clinical presentation."
- reference: PMID:19587327
  title: Hearing improvement after bevacizumab in patients with neurofibromatosis type 2.
- reference: PMID:20301380
  title: NF2-Related Schwannomatosis.
  tags:
  - GeneReviews
- reference: PMID:40470965
  title: "Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline on Surgical Resection for the Treatment of Patients With Vestibular Schwannomas: Update."
- reference: PMID:40470968
  title: Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines Update for the Role of Audiologic Screening in the Diagnosis and Management of Patients With Vestibular Schwannomas.
pathophysiology:
- name: Biallelic NF2 Inactivation and Merlin Loss
  role: trigger
  description: >-
    In the predominant sporadic form, pathogenic NF2 alterations and/or loss
    of the second NF2 allele occur in tumor tissue and eliminate merlin
    tumor-suppressor activity. Germline NF2 predisposition followed by a
    somatic second hit produces the analogous lesion in NF2-related tumors.
  cell_types:
  - preferred_term: Schwann cell
    term:
      id: CL:0002573
      label: Schwann cell
  genes:
  - preferred_term: NF2
    term:
      id: hgnc:7773
      label: NF2
  evidence:
  - reference: PMID:39941762
    reference_title: Genetic Alterations in Patients with NF2-Related Schwannomatosis and Sporadic Vestibular Schwannomas.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Biallelic NF2 inactivation primarily drives vestibular schwannoma tumorigenesis."
    explanation: Paired lymphocyte and tumor-DNA analysis directly supports biallelic NF2 inactivation in both sporadic unilateral and NF2-related tumors.
  - reference: PMID:40295009
    reference_title: Pathogenic Variants and Allele Loss of the NF2 and LZTR1 Gene in Sporadic Vestibular Schwannoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pathogenic variants and allele-loss of the NF2 gene with Merlin loss as consequence is the driving genetic event for vestibular schwannoma development."
    explanation: Sequencing of sporadic tumors identifies NF2 alteration or allele loss as the principal genetic event.
  - reference: PMID:28710469
    reference_title: Differential NF2 Gene Status in Sporadic Vestibular Schwannomas and its Prognostic Impact on Tumour Growth Patterns.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The great majority of sporadic vestibular schwannomas (VSs) are due to the inactivation of the NF2 gene."
    explanation: Human sporadic-tumor data support NF2 inactivation as the upstream lesion.
  downstream:
  - target: Loss of Merlin-Dependent Contact Inhibition and Receptor Control
    causal_link_type: DIRECT
    description: >-
      Merlin loss removes contact-dependent restriction of growth-factor
      receptor delivery and mitogenic signaling in Schwann cells.
    evidence:
    - reference: PMID:19029950
      reference_title: Merlin regulates transmembrane receptor accumulation and signaling at the plasma membrane in primary mouse Schwann cells and in human schwannomas.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "loss of merlin activity is associated with elevated levels of ErbB receptors in primary SCs."
      explanation: Loss of merlin directly disrupts receptor control in primary Schwann cells.
  - target: YAP/TAZ-TEAD-Dependent Mitogenic Signaling
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Hippo-pathway kinase regulation
    description: >-
      NF2-null schwannoma cells acquire dependence on YAP/TAZ-driven TEAD
      transcriptional output through the Hippo pathway.
    evidence:
    - reference: PMID:36148553
      reference_title: Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "driven by the TAZ protein in human and mouse NF2-null schwannoma cells"
      explanation: TAZ activity in NF2-null schwannoma cells supports the downstream relationship, while the intervening merlin-to-Hippo steps are not represented in this graph.
- name: Loss of Merlin-Dependent Contact Inhibition and Receptor Control
  role: central_effector
  description: >-
    Merlin normally limits delivery of growth-factor receptors to the
    Schwann-cell surface at cell-cell contact and restrains downstream AKT and MAPK
    signaling. Merlin loss weakens contact inhibition and permits excess
    mitogenic receptor signaling.
  cell_types:
  - preferred_term: Schwann cell
    term:
      id: CL:0002573
      label: Schwann cell
  biological_processes:
  - preferred_term: contact inhibition
    modifier: DECREASED
    term:
      id: GO:0060242
      label: contact inhibition
  evidence:
  - reference: PMID:19029950
    reference_title: Merlin regulates transmembrane receptor accumulation and signaling at the plasma membrane in primary mouse Schwann cells and in human schwannomas.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "merlin regulates contact inhibition of proliferation by limiting the delivery of several growth factor receptors at the plasma membrane of primary SCs."
    explanation: Primary Schwann-cell experiments directly define merlin's contact-dependent receptor-control function.
  downstream:
  - target: Vestibular Schwannoma Formation and Tumor Growth
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - ErbB/AKT and MAPK mitogenic signaling
    description: Loss of contact-dependent restraint permits neoplastic Schwann-cell proliferation.
    evidence:
    - reference: PMID:19029950
      reference_title: Merlin regulates transmembrane receptor accumulation and signaling at the plasma membrane in primary mouse Schwann cells and in human schwannomas.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "We also observed accumulation of growth factor receptors such as ErbB2 and 3, insulin-like growth factor 1 receptor and platelet-derived growth factor receptor in peripheral nerves of Nf2-mutant mice"
      explanation: Nf2-mutant mouse nerves show receptor accumulation, supporting this candidate route without isolating the intervening mitogenic steps.
    - reference: PMID:19029950
      reference_title: Merlin regulates transmembrane receptor accumulation and signaling at the plasma membrane in primary mouse Schwann cells and in human schwannomas.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "in human NF2 schwannomas, suggesting that this mechanism could play an important role in tumorigenesis."
      explanation: Human NF2 schwannomas provide corroborating tumor evidence, while the source explicitly frames the mechanistic interpretation as suggestive.
- name: YAP/TAZ-TEAD-Dependent Mitogenic Signaling
  role: central_effector
  description: >-
    NF2-null schwannoma cells depend on YAP/TAZ-driven TEAD transcriptional
    activity. Genetic YAP/TAZ ablation or pharmacologic TEAD inhibition blocks
    and can regress schwannoma growth in primary-cell and mouse models, making
    this a preclinical rather than approved clinical target.
  cell_types:
  - preferred_term: Schwann cell
    term:
      id: CL:0002573
      label: Schwann cell
  biological_processes:
  - preferred_term: positive regulation of Schwann cell proliferation
    modifier: INCREASED
    term:
      id: GO:0010625
      label: positive regulation of Schwann cell proliferation
  evidence:
  - reference: PMID:36148553
    reference_title: Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Hippo signalling may be successfully targeted in vitro"
    explanation: In-vitro perturbation directly supports YAP/TAZ-TEAD dependence in schwannoma cells.
  - reference: PMID:36148553
    reference_title: Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "successful use of TEAD palmitoylation inhibitors in a preclinical mouse model of schwannoma points to their potential future clinical use."
    explanation: A preclinical mouse model independently supports in-vivo targetability of TEAD activity.
  downstream:
  - target: Vestibular Schwannoma Formation and Tumor Growth
    causal_link_type: DIRECT
    description: YAP/TAZ-driven TEAD transcription sustains NF2-null schwannoma growth.
    evidence:
    - reference: PMID:36148553
      reference_title: Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "successful use of TEAD palmitoylation inhibitors in a preclinical mouse model of schwannoma points to their potential future clinical use."
      explanation: In-vivo TEAD inhibition suppresses schwannoma growth, supporting the causal link while remaining preclinical.
- name: Vestibular Schwannoma Formation and Tumor Growth
  role: pathological_process
  description: >-
    Proliferating neoplastic Schwann cells form a benign tumor on a vestibular
    division of cranial nerve VIII. Tumors may remain intrameatal or extend into
    the cerebellopontine angle; growth rate and clinical effects vary widely.
  cell_types:
  - preferred_term: Schwann cell
    term:
      id: CL:0002573
      label: Schwann cell
  locations:
  - preferred_term: vestibulocochlear nerve
    term:
      id: UBERON:0001648
      label: vestibulocochlear nerve
  - preferred_term: internal acoustic meatus
    term:
      id: UBERON:0011859
      label: internal acoustic meatus
  biological_processes:
  - preferred_term: positive regulation of Schwann cell proliferation
    modifier: INCREASED
    term:
      id: GO:0010625
      label: positive regulation of Schwann cell proliferation
  evidence:
  - reference: PMID:28710469
    reference_title: Differential NF2 Gene Status in Sporadic Vestibular Schwannomas and its Prognostic Impact on Tumour Growth Patterns.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Following the loss of NF2 expression, schwannoma cultures demonstrated increased proliferation rates."
    explanation: NF2 loss increases proliferation in human sporadic schwannoma cultures.
  downstream:
  - target: Vestibular Schwannoma Secretome and Cochlear Injury
    causal_link_type: DIRECT
    description: Tumor-derived soluble factors can damage cochlear hair cells and neurites independently of a simple compression-only model.
    evidence:
    - reference: PMID:26690506
      reference_title: Secreted Factors from Human Vestibular Schwannomas Can Cause Cochlear Damage.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "Our results are the first to demonstrate that secreted factors from VSs can lead to cochlear damage."
      explanation: Human tumor-conditioned media directly damaged cochlear explants.
  - target: Eighth-Nerve Auditory and Vestibular Dysfunction
    causal_link_type: DIRECT
    description: Tumor involvement of cranial nerve VIII disrupts auditory and vestibular function.
    evidence:
    - reference: PMID:25794859
      reference_title: Prevalence of vestibular dysfunction in patients with vestibular schwannoma using video head-impulses and vestibular-evoked potentials.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The sensitivity of the 5-item battery increased with tumour size and all patients with medium to large (>14 mm) schwannoma had at least two abnormal vestibular test result."
      explanation: Objective vestibular abnormalities increase with tumor size, supporting a clinical tumor-to-nerve dysfunction link without proving a single molecular intermediary.
  - target: Cerebellopontine-Angle Expansion and Advanced Mass Effect
    causal_link_type: DIRECT
    description: Extrameatal growth can compress adjacent cranial nerves and the brainstem.
    evidence:
    - reference: PMID:8971818
      reference_title: "Management of 1000 vestibular schwannomas (acoustic neuromas): clinical presentation."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Key symptoms of various tumor extension classes precipitated the diagnosis, such as trigeminal disturbances in large tumors with brain stem compression or tinnitus in small neuromas."
      explanation: The large clinical series links advanced tumor extension and brainstem compression to adjacent-nerve symptoms.
- name: Vestibular Schwannoma Secretome and Cochlear Injury
  role: consequence
  description: >-
    Soluble factors released by vestibular schwannomas can injure cochlear hair
    cells and neuronal fibers. Human temporal-bone pathology corroborates
    ipsilateral cochlear degeneration, although the relative contributions of
    secreted factors and retrocochlear injury remain uncertain.
  locations:
  - preferred_term: cochlea
    term:
      id: UBERON:0001844
      label: cochlea
  evidence:
  - reference: PMID:26690506
    reference_title: Secreted Factors from Human Vestibular Schwannomas Can Cause Cochlear Damage.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Secretions from tumours associated with most substantial SNHL resulted in most significant hair cell loss and neuronal fibre disorganization."
    explanation: Conditioned-media experiments link human tumor secretions to cochlear cellular injury.
  - reference: PMID:22377650
    reference_title: "Dysfunction of the cochlea contributing to hearing loss in acoustic neuromas: an underappreciated entity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "VS caused significantly more inner and outer hair cell loss, cochlear neuronal loss, precipitate in endolymph and perilymph, and decreased pure tone average, when compared with the opposite ear."
    explanation: Human temporal-bone histology corroborates ipsilateral cochlear degeneration.
  downstream:
  - target: Sensorineural Hearing Impairment
    causal_link_type: DIRECT
    description: Cochlear hair-cell and neuronal degeneration contributes to sensorineural hearing loss.
    evidence:
    - reference: PMID:22377650
      reference_title: "Dysfunction of the cochlea contributing to hearing loss in acoustic neuromas: an underappreciated entity."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Cochlear dysfunction may be an important contributor to the hearing loss caused by VS and can explain certain clinically observed phenomena in patients with VS."
      explanation: Human pathology directly supports cochlear dysfunction as a contributor to hearing loss.
- name: Eighth-Nerve Auditory and Vestibular Dysfunction
  role: consequence
  description: >-
    Vestibular schwannoma disrupts cranial-nerve VIII function, producing
    auditory symptoms and objective dysfunction of superior and inferior
    vestibular divisions. Central compensation helps explain why objective
    vestibular deficits and perceived vertigo do not always align.
  locations:
  - preferred_term: vestibulocochlear nerve
    term:
      id: UBERON:0001648
      label: vestibulocochlear nerve
  evidence:
  - reference: PMID:25794859
    reference_title: Prevalence of vestibular dysfunction in patients with vestibular schwannoma using video head-impulses and vestibular-evoked potentials.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Our results indicate that dysfunction of the superior and inferior vestibular nerve evolves in parallel for most patients with schwannoma."
    explanation: Objective human testing documents dysfunction of both vestibular nerve divisions.
  downstream:
  - target: Sensorineural Hearing Impairment
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Retrocochlear auditory-nerve dysfunction is one contributor to sensorineural hearing impairment, alongside the parallel cochlear-injury branch.
    evidence:
    - reference: PMID:22377650
      reference_title: "Dysfunction of the cochlea contributing to hearing loss in acoustic neuromas: an underappreciated entity."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Clinical and histologic observations have suggested that the hearing loss may be caused by both retrocochlear and cochlear mechanisms."
      explanation: Human observations suggest a retrocochlear contribution in parallel with cochlear injury but do not isolate a single nerve-to-hearing-loss route.
  - target: Tinnitus
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Vestibular schwannoma-associated auditory-pathway dysfunction can present with tinnitus, but the exact causal intermediary is unresolved.
    evidence:
    - reference: PMID:8971818
      reference_title: "Management of 1000 vestibular schwannomas (acoustic neuromas): clinical presentation."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Key symptoms of various tumor extension classes precipitated the diagnosis, such as trigeminal disturbances in large tumors with brain stem compression or tinnitus in small neuromas."
      explanation: The clinical series links tinnitus to small vestibular schwannomas but does not establish a single causal pathway.
  - target: Abnormal Vestibular Function
    causal_link_type: DIRECT
    description: Superior and inferior vestibular nerve dysfunction produces abnormal vestibular testing and may manifest as disequilibrium or vertigo.
    evidence:
    - reference: PMID:25794859
      reference_title: Prevalence of vestibular dysfunction in patients with vestibular schwannoma using video head-impulses and vestibular-evoked potentials.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The percentage of abnormalities for each of the five tests for the entire sample ranged between 36.2-61.7%."
      explanation: Multiple objective vestibular tests were abnormal in a substantial fraction of patients.
- name: Cerebellopontine-Angle Expansion and Advanced Mass Effect
  role: consequence
  description: >-
    Larger extrameatal tumors can compress the brainstem and adjacent cranial
    nerves in the cerebellopontine angle. Trigeminal manifestations are a
    conditional advanced-tumor effect, not a universal feature.
  locations:
  - preferred_term: cerebellopontine angle
    term:
      id: UBERON:0014908
      label: cerebellopontine angle
  evidence:
  - reference: PMID:8971818
    reference_title: "Management of 1000 vestibular schwannomas (acoustic neuromas): clinical presentation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Key symptoms of various tumor extension classes precipitated the diagnosis, such as trigeminal disturbances in large tumors with brain stem compression or tinnitus in small neuromas."
    explanation: A 1,000-patient clinical series associates large tumors and brainstem compression with trigeminal symptoms without proving every local mass-effect step.
  downstream:
  - target: Trigeminal Sensory Disturbance
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - brainstem compression
    description: Large tumors can produce trigeminal sensory symptoms through local mass effect.
    evidence:
    - reference: PMID:8971818
      reference_title: "Management of 1000 vestibular schwannomas (acoustic neuromas): clinical presentation."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Key symptoms of various tumor extension classes precipitated the diagnosis, such as trigeminal disturbances in large tumors with brain stem compression or tinnitus in small neuromas."
      explanation: The clinical series specifically links trigeminal disturbance to large tumors with brainstem compression.
phenotypes:
- name: Sensorineural Hearing Impairment
  description: >-
    Usually asymmetric or unilateral sensorineural hearing impairment is the
    dominant functional manifestation. Both retrocochlear eighth-nerve effects
    and ipsilateral cochlear degeneration may contribute.
  phenotype_term:
    preferred_term: Sensorineural hearing impairment
    term:
      id: HP:0000407
      label: Sensorineural hearing impairment
  evidence:
  - reference: PMID:22377650
    reference_title: "Dysfunction of the cochlea contributing to hearing loss in acoustic neuromas: an underappreciated entity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Hearing loss is a common symptom in patients with cochleovestibular schwannoma."
    explanation: Human clinicopathologic data directly support hearing loss as a common manifestation.
- name: Tinnitus
  description: >-
    Tinnitus may occur even with a small tumor and can be a major source of
    quality-of-life impairment; its relationship to tumor size and hearing
    status is heterogeneous.
  phenotype_term:
    preferred_term: Tinnitus
    term:
      id: HP:0000360
      label: Tinnitus
  evidence:
  - reference: PMID:38892775
    reference_title: "Vestibular Schwannoma and Tinnitus: A Systematic Review of Microsurgery Compared to Gamma Knife Radiosurgery."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Although VS can cause a variety of symptoms, tinnitus is one of the most distressing symptoms for patients and can greatly impact quality of life."
    explanation: The systematic review supports tinnitus as a clinically important manifestation.
- name: Abnormal Vestibular Function
  description: >-
    Dysfunction of superior and inferior vestibular nerve divisions can produce
    objective vestibular-test abnormalities and may be perceived as imbalance,
    disequilibrium, or vertigo.
  phenotype_term:
    preferred_term: Abnormal vestibular function
    term:
      id: HP:0001751
      label: Abnormal vestibular function
  evidence:
  - reference: PMID:25794859
    reference_title: Prevalence of vestibular dysfunction in patients with vestibular schwannoma using video head-impulses and vestibular-evoked potentials.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Unexplained vHIT and VEMP asymmetry should alert otologists and neurologists to undertake imaging in patients presenting with non-specific disequilibrium or vertigo."
    explanation: Objective vestibular testing and associated disequilibrium/vertigo support the broad vestibular phenotype.
- name: Trigeminal Sensory Disturbance
  description: >-
    Trigeminal sensory disturbance is primarily an advanced-tumor manifestation
    associated with large lesions and brainstem compression. No sufficiently
    broad HPO term was assigned; trigeminal anesthesia would be too narrow.
  phenotype_term:
    preferred_term: Trigeminal sensory disturbance
  evidence:
  - reference: PMID:8971818
    reference_title: "Management of 1000 vestibular schwannomas (acoustic neuromas): clinical presentation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Key symptoms of various tumor extension classes precipitated the diagnosis, such as trigeminal disturbances in large tumors with brain stem compression or tinnitus in small neuromas."
    explanation: This directly supports trigeminal symptoms as a large-tumor presentation.
genetic:
- name: Somatic NF2 inactivation in sporadic vestibular schwannoma
  subtype: Sporadic Unilateral
  gene_term:
    preferred_term: NF2
    term:
      id: hgnc:7773
      label: NF2
  association: Somatic NF2 pathogenic variants and allele loss drive the predominant sporadic tumor context.
  relationship_type: SOMATIC_DRIVER
  variant_origin: SOMATIC
  evidence:
  - reference: PMID:39941762
    reference_title: Genetic Alterations in Patients with NF2-Related Schwannomatosis and Sporadic Vestibular Schwannomas.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "patients with uVS often exhibit one NF2 variant with LOH."
    explanation: Paired tumor and lymphocyte analysis supports somatic two-hit NF2 inactivation in unilateral vestibular schwannoma.
  - reference: PMID:40295009
    reference_title: Pathogenic Variants and Allele Loss of the NF2 and LZTR1 Gene in Sporadic Vestibular Schwannoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Among the 41 tumor samples, 34 had one pathogenic variant or an allele-loss of NF2 gene and one tumor showed a pathogenic variant in the LZTR1 gene."
    explanation: Tumor sequencing demonstrates frequent somatic NF2 alteration or allele loss in sporadic vestibular schwannoma.
  - reference: PMID:40295009
    reference_title: Pathogenic Variants and Allele Loss of the NF2 and LZTR1 Gene in Sporadic Vestibular Schwannoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "none of these variants was found in blood."
    explanation: Absence from blood supports a somatic rather than inherited origin in this cohort.
- name: Germline NF2 predisposition in NF2-related vestibular schwannoma
  subtype: NF2-Related
  gene_term:
    preferred_term: NF2
    term:
      id: hgnc:7773
      label: NF2
  association: Germline NF2 pathogenic variants predispose to bilateral vestibular schwannomas in the NF2-related syndrome context.
  relationship_type: RISK_FACTOR
  variant_origin: GERMLINE
  evidence:
  - reference: PMID:20301380
    reference_title: NF2-Related Schwannomatosis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "NF2 is inherited in an autosomal dominant manner."
    explanation: GeneReviews establishes germline NF2 as the inherited predisposition context.
imaging_findings:
- name: Vestibular schwannoma visible on MRI
  modality: MRI
  imaging_finding_term:
    preferred_term: Vestibular schwannoma
    term:
      id: HP:0009588
      label: Vestibular schwannoma
  located_in:
    preferred_term: vestibulocochlear nerve
    term:
      id: UBERON:0001648
      label: vestibulocochlear nerve
  phenotype_term:
    preferred_term: Vestibular schwannoma
    term:
      id: HP:0009588
      label: Vestibular schwannoma
  diagnostic: true
  notes: >-
    MRI defines the radiologic diagnosis. The lesion arises on a vestibular
    division of cranial nerve VIII and may extend from the internal acoustic
    meatus into the cerebellopontine angle.
  evidence:
  - reference: PMID:31504802
    reference_title: EANO guideline on the diagnosis and treatment of vestibular schwannoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The radiological diagnosis of vestibular schwannoma is made by magnetic resonance imaging."
    explanation: The EANO guideline identifies MRI as the radiologic diagnostic method.
  - reference: PMID:28710469
    reference_title: Differential NF2 Gene Status in Sporadic Vestibular Schwannomas and its Prognostic Impact on Tumour Growth Patterns.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Vestibular schwannomas (VSs) are benign tumours that originate from myelin-forming schwann cells that surround the vestibular branches of the 8th (auditory) cranial nerve."
    explanation: Human tumor data supply the anatomic origin represented by the imaging finding.
diagnosis:
- name: Magnetic resonance imaging
  description: >-
    MRI establishes the radiologic diagnosis, characterizes intrameatal and
    cerebellopontine-angle extent, and provides the baseline for subsequent
    growth surveillance. Histologic verification is not always required.
  diagnosis_term:
    preferred_term: magnetic resonance imaging procedure
    term:
      id: NCIT:C16809
      label: Magnetic Resonance Imaging
  results: MRI demonstrates a lesion compatible with vestibular schwannoma on cranial nerve VIII.
  evidence:
  - reference: PMID:31504802
    reference_title: EANO guideline on the diagnosis and treatment of vestibular schwannoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The radiological diagnosis of vestibular schwannoma is made by magnetic resonance imaging. Histological verification of the diagnosis is not always required."
    explanation: The guideline directly supports MRI-based diagnosis without mandatory tissue confirmation.
- name: Audiologic assessment
  description: >-
    Pure-tone and speech audiometry characterize asymmetric hearing loss and
    provide a functional baseline. Audiologic symptoms prompt MRI screening but
    are not specific for vestibular schwannoma.
  diagnosis_term:
    preferred_term: hearing examination
    term:
      id: NCIT:C38036
      label: Audiometric Test
  results: Quantifies hearing thresholds and speech discrimination and identifies asymmetric or unilateral sensorineural hearing loss.
  evidence:
  - reference: PMID:40470968
    reference_title: Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines Update for the Role of Audiologic Screening in the Diagnosis and Management of Patients With Vestibular Schwannomas.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We aim to assess the diagnostic yield of MRI in the detection of VS in patients presenting with asymmetric sensorineural hearing loss (SNHL), unilateral tinnitus, and sudden SNHL."
    explanation: The current CNS guideline connects audiologic presentations to diagnostic MRI screening for vestibular schwannoma.
  - reference: PMID:19587327
    reference_title: Hearing improvement after bevacizumab in patients with neurofibromatosis type 2.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Hearing response was monitored with the use of serial audiologic evaluations, including determination of pure-tone thresholds and word-recognition scores"
    explanation: A vestibular-schwannoma clinical study directly documents the pure-tone and word-recognition measures named in this assessment.
treatments:
- name: Observation with Serial MRI and Audiometry
  description: >-
    Observation is appropriate for selected patients based on tumor size,
    symptoms, hearing, documented growth, age, comorbidity, and preference.
    Limited initial growth does not invariably require immediate intervention.
  action_category: MONITORING
  treatment_term:
    preferred_term: observation
    term:
      id: NCIT:C25598
      label: Observation Activity
  evidence:
  - reference: PMID:31504802
    reference_title: EANO guideline on the diagnosis and treatment of vestibular schwannoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Current treatment options include observation, surgical resection, fractionated radiotherapy, and radiosurgery."
    explanation: EANO recognizes observation as a core management option.
  - reference: PMID:34121081
    reference_title: "Natural History of Growing Sporadic Vestibular Schwannomas During Observation: An International Multi-Institutional Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Because early treatment does not confer improved long-term quality of life outcomes, toleration of some growth during observation is justifiable in appropriately selected cases."
    explanation: Cohort evidence supports continued surveillance in carefully selected patients.
- name: Microsurgical Resection
  description: >-
    Microsurgery removes or decompresses tumor when size, mass effect,
    progression, symptoms, hearing goals, or patient factors favor operative
    treatment. Approach and extent must balance tumor control against hearing
    and facial-nerve morbidity.
  action_category: THERAPEUTIC
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: NCIT:C15329
      label: Surgical Procedure
  target_mechanisms:
  - target: Cerebellopontine-Angle Expansion and Advanced Mass Effect
    treatment_effect: INHIBITS
    description: Resection removes or decompresses advanced local tumor burden; INHIBITS is the closest available treatment-effect category for that reduction.
    evidence:
    - reference: PMID:31504802
      reference_title: EANO guideline on the diagnosis and treatment of vestibular schwannoma.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "In small tumors, observation has to be weighed against radiosurgery, in large tumors surgical decompression is mandatory, potentially followed by fractionated radiotherapy or radiosurgery."
      explanation: The guideline directly supports surgical decompression as the tumor-burden intervention for large lesions.
  evidence:
  - reference: PMID:40470965
    reference_title: "Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline on Surgical Resection for the Treatment of Patients With Vestibular Schwannomas: Update."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Surgical intervention remains an important option in the management of vestibular schwannoma (VSs)."
    explanation: The updated CNS guideline supports surgery as a central management option.
- name: Stereotactic Radiosurgery or Fractionated Radiotherapy
  description: >-
    Radiation-based local therapy is selected according to tumor size,
    location, symptoms, prior treatment, and patient factors. Comparative
    estimates are dominated by nonrandomized studies and should not be read as
    universal superiority over observation or surgery.
  action_category: THERAPEUTIC
  therapeutic_modality: RADIOTHERAPY
  treatment_term:
    preferred_term: radiation therapy
    term:
      id: NCIT:C15313
      label: Radiation Therapy
  target_mechanisms:
  - target: Vestibular Schwannoma Formation and Tumor Growth
    treatment_effect: INHIBITS
    description: Radiosurgery or fractionated radiotherapy aims for local tumor control rather than direct pathway-specific YAP/TAZ inhibition.
    evidence:
    - reference: PMID:39627752
      reference_title: "Treatment options for unilateral vestibular schwannoma: a network meta-analysis."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "We found the MS, and different SRS all had better tumor local control rates."
      explanation: The network meta-analysis supports local tumor control, with partial support because almost all included studies were nonrandomized.
  evidence:
  - reference: PMID:31504802
    reference_title: EANO guideline on the diagnosis and treatment of vestibular schwannoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Current treatment options include observation, surgical resection, fractionated radiotherapy, and radiosurgery."
    explanation: EANO recognizes both fractionated radiotherapy and radiosurgery as core options.
- name: Bevacizumab for Selected NF2-Related Vestibular Schwannoma
  description: >-
    Bevacizumab is a systemic anti-VEGF option for selected patients with
    progressive NF2-related vestibular schwannomas, particularly when standard
    local treatments are unsuitable. Responses are variable, and this evidence
    should not be generalized to routine sporadic unilateral disease.
  context: Progressive NF2-related vestibular schwannoma in selected patients
  action_category: THERAPEUTIC
  therapeutic_modality: MONOCLONAL_ANTIBODY
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: bevacizumab
      term:
        id: NCIT:C2039
        label: Bevacizumab
  target_mechanisms:
  - target: Vestibular Schwannoma Formation and Tumor Growth
    treatment_effect: INHIBITS
    description: VEGF blockade can reduce tumor volume in some progressive NF2-related tumors; this is a context-specific clinical effect, not proof that VEGF drives every sporadic tumor.
    evidence:
    - reference: PMID:19587327
      reference_title: Hearing improvement after bevacizumab in patients with neurofibromatosis type 2.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "VEGF blockade with bevacizumab improved hearing in some, but not all, patients with neurofibromatosis type 2 and was associated with a reduction in the volume of most growing vestibular schwannomas."
      explanation: The clinical series directly supports tumor-volume reduction in the selected NF2-related context.
  evidence:
  - reference: PMID:19587327
    reference_title: Hearing improvement after bevacizumab in patients with neurofibromatosis type 2.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "After bevacizumab treatment in the 10 patients, tumors shrank in 9 patients, and 6 patients had an imaging response, which was maintained in 4 patients during 11 to 16 months of follow-up."
    explanation: The initial NF2-related series documents heterogeneous but clinically meaningful imaging responses.
animal_models:
- species: mouse
  genotype: Schwannoma mouse model used for YAP/TAZ-TEAD perturbation
  category: Genetic and transplant schwannoma models
  genes:
  - preferred_term: NF2
    term:
      id: hgnc:7773
      label: NF2
  description: >-
    A preclinical mouse schwannoma model was used with YAP/TAZ-TEAD perturbation
    to test whether Hippo-effector activity is required for tumor growth.
  associated_phenotypes:
  - Schwannoma tumor growth
  evidence:
  - reference: PMID:36148553
    reference_title: Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "successful use of TEAD palmitoylation inhibitors in a preclinical mouse model of schwannoma points to their potential future clinical use."
    explanation: The abstract directly documents an in-vivo mouse schwannoma treatment model without requiring an unsupported strain-level genotype.
experimental_models:
- name: Human primary schwannoma-cell model
  description: >-
    Human primary schwannoma cells are used to examine YAP/TAZ-TEAD activity
    and its response to genetic or pharmacologic perturbation.
  experimental_model_type: PRIMARY_CELL_CULTURE
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  cell_types:
  - preferred_term: Schwann cell
    term:
      id: CL:0002573
      label: Schwann cell
  conditions:
  - Human primary schwannoma cells
  - YAP/TAZ genetic or TEAD pharmacologic perturbation
  cell_source: Human primary schwannoma tumor cells
  modeled_mechanisms:
  - target: YAP/TAZ-TEAD-Dependent Mitogenic Signaling
    description: Genetic and pharmacologic perturbations test YAP/TAZ-TEAD dependence.
    evidence:
    - reference: PMID:36148553
      reference_title: Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "Hippo signalling may be successfully targeted in vitro"
      explanation: The in-vitro result directly supports use of the primary-cell system to interrogate YAP/TAZ-TEAD dependence.
  findings:
  - statement: ALDH1A1 is a TAZ-driven Hippo-signaling target in human NF2-null schwannoma cells.
    supporting_text: The study identifies a TAZ-linked cellular target in human NF2-null schwannoma cells, with parallel mouse-cell confirmation.
    evidence:
    - reference: PMID:36148553
      reference_title: Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "driven by the TAZ protein in human and mouse NF2-null schwannoma cells"
      explanation: This cellular finding directly supports the human NF2-null schwannoma-cell component while also reporting mouse-cell confirmation.
  evidence:
  - reference: PMID:36148553
    reference_title: Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Using a combination of human primary tumour cells"
    explanation: This directly identifies the human primary-cell component of the model.
- name: Human vestibular-schwannoma secretions on murine cochlear explants
  description: >-
    Conditioned media from resected human unilateral sporadic vestibular
    schwannomas are applied to murine cochlear explants to test tumor-secreted
    injury to hair cells and neuronal fibers.
  experimental_model_type: OTHER
  organism:
    preferred_term: house mouse
    term:
      id: NCBITaxon:10090
      label: Mus musculus
  conditions:
  - Human vestibular schwannoma-conditioned medium
  cell_source: Neonatal murine cochlear explants exposed to secretions from human tumors
  modeled_mechanisms:
  - target: Vestibular Schwannoma Secretome and Cochlear Injury
    description: The cross-species explant assay tests whether soluble human tumor products can injure cochlear cells.
    evidence:
    - reference: PMID:26690506
      reference_title: Secreted Factors from Human Vestibular Schwannomas Can Cause Cochlear Damage.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "murine cochlear explant cultures were treated with human tumour secretions from thirteen different unilateral, sporadic VSs of subjects demonstrating varied degrees of ipsilateral SNHL."
      explanation: This sentence directly defines the model system and modeled mechanism.
  findings:
  - statement: Secretions from tumors associated with greater hearing loss produced greater cochlear hair-cell loss and neuronal-fiber disorganization.
    supporting_text: Cochlear explant damage roughly tracked the hearing loss of the patient whose tumor supplied the secretions.
    evidence:
    - reference: PMID:26690506
      reference_title: Secreted Factors from Human Vestibular Schwannomas Can Cause Cochlear Damage.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "Secretions from tumours associated with most substantial SNHL resulted in most significant hair cell loss and neuronal fibre disorganization."
      explanation: The conditioned-media experiment directly supports the model finding.
  evidence:
  - reference: PMID:26690506
    reference_title: Secreted Factors from Human Vestibular Schwannomas Can Cause Cochlear Damage.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Our results are the first to demonstrate that secreted factors from VSs can lead to cochlear damage."
    explanation: The study supports the experimental model's central disease-mechanism claim.
discussions:
- discussion_id: mismatch_acoustic_preclinical_models_and_human_function
  prompt: >-
    How faithfully do Nf2-null mouse tumors, isolated human primary cells, and
    murine cochlear explants reproduce the human eighth-nerve anatomy, immune
    and vascular microenvironment, hearing loss, tinnitus, and vestibular
    natural history of sporadic vestibular schwannoma?
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  attaches_to:
  - pathophysiology#YAP/TAZ-TEAD-Dependent Mitogenic Signaling
  - pathophysiology#Vestibular Schwannoma Secretome and Cochlear Injury
  rationale: >-
    The YAP/TAZ study establishes tumor-growth dependence in primary cells and
    mouse models, but not human auditory outcomes. The secretome experiment
    applies human tumor products to murine cochlear explants, establishing
    plausibility but not the in-vivo fraction of human hearing loss caused by
    soluble factors. A human multicellular model preserving tumor, nerve,
    cochlear, immune, and vascular interactions is needed to bridge these gaps.
  proposed_experiments:
  - experiment_id: exp_acoustic_human_tumor_nerve_cochlea_coculture
    name: Patient-derived vestibular schwannoma, auditory-neuron, and cochlear co-culture
    description: >-
      Compare patient-derived NF2-null tumor cells and isogenic NF2-restored
      controls in a human multicellular co-culture containing auditory neurons
      and cochlear sensory cells; perturb TEAD and neutralize candidate
      secreted factors while measuring tumor growth, neurite integrity,
      hair-cell survival, and electrophysiologic function.
    experiment_type:
      preferred_term: human multicellular tumor-neural co-culture perturbation assay
    model_systems:
    - name: Human vestibular schwannoma-auditory pathway co-culture
      description: Human patient-derived tumor cells combined with auditory-neural and cochlear sensory-cell compartments.
      experimental_model_type: CO_CULTURE
      organism:
        preferred_term: human
        term:
          id: NCBITaxon:9606
          label: Homo sapiens
  evidence:
  - reference: PMID:36148553
    reference_title: Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "successful use of TEAD palmitoylation inhibitors in a preclinical mouse model of schwannoma points to their potential future clinical use."
    explanation: The explicitly preclinical framing motivates a human translational bridge.
  - reference: PMID:26690506
    reference_title: Secreted Factors from Human Vestibular Schwannomas Can Cause Cochlear Damage.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "murine cochlear explant cultures were treated with human tumour secretions from thirteen different unilateral, sporadic VSs"
    explanation: The cross-species design defines the fidelity question for cochlear injury.
- discussion_id: interpretation_acoustic_hearing_not_size_only
  prompt: >-
    What proportions of vestibular-schwannoma-associated hearing loss arise
    from retrocochlear nerve effects, mechanical compression, cochlear
    degeneration, or tumor-secreted factors, and why can hearing severity
    diverge from tumor size?
  kind: INTERPRETATION
  status: OPEN
  attaches_to:
  - pathophysiology#Vestibular Schwannoma Formation and Tumor Growth
  - pathophysiology#Vestibular Schwannoma Secretome and Cochlear Injury
  rationale: >-
    Human temporal-bone data show cochlear degeneration, while tumor size and
    distance from the cochlea did not correlate with structural cochlear change
    or hearing threshold. A compression-only graph would therefore overstate
    what is known; the entry retains parallel local-nerve and secretome/cochlear
    branches.
  evidence:
  - reference: PMID:22377650
    reference_title: "Dysfunction of the cochlea contributing to hearing loss in acoustic neuromas: an underappreciated entity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Tumor size, distance from the cochlea, and nerve of origin did not correlate with structural changes in the cochlea or the hearing threshold."
    explanation: Human pathology supports a mechanism more complex than tumor size or proximity alone.
- discussion_id: interpretation_acoustic_treatment_comparisons
  prompt: >-
    How should observation, radiosurgery, fractionated radiotherapy, and
    microsurgery be compared when tumor size, symptoms, hearing, age, and other
    selection factors differ across mostly nonrandomized studies?
  kind: INTERPRETATION
  status: OPEN
  attaches_to:
  - treatments#Observation with Serial MRI and Audiometry
  - treatments#Microsurgical Resection
  - treatments#Stereotactic Radiosurgery or Fractionated Radiotherapy
  rationale: >-
    Guidelines emphasize individualized selection and explicitly characterize
    the evidence base as low. Network rankings are heavily influenced by
    observational cohorts and should not be read as causal head-to-head
    superiority for every patient.
  evidence:
  - reference: PMID:31504802
    reference_title: EANO guideline on the diagnosis and treatment of vestibular schwannoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The level of evidence to provide treatment recommendations for vestibular schwannoma is low compared with other intracranial neoplasms."
    explanation: EANO explicitly identifies the limited comparative evidence base.
  - reference: PMID:39627752
    reference_title: "Treatment options for unilateral vestibular schwannoma: a network meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "34 non-RCTs and 1 RCT that included 6 interventions were analyzed."
    explanation: The network meta-analysis is overwhelmingly based on nonrandomized studies.
📚

References & Deep Research

References

17
PMID:31504802
EANO guideline on the diagnosis and treatment of vestibular schwannoma.
No top-level findings curated for this source.
PMID:34464224
Global Incidence of Sporadic Vestibular Schwannoma: A Systematic Review.
No top-level findings curated for this source.
PMID:30688755
Prevalence of Sporadic Vestibular Schwannoma: Reconciling Temporal Bone, Radiologic, and Population-based Studies.
No top-level findings curated for this source.
PMID:33068429
The natural history of vestibular schwannoma growth-prospective 40-year data from an unselected national cohort.
No top-level findings curated for this source.
PMID:28710469
Differential NF2 Gene Status in Sporadic Vestibular Schwannomas and its Prognostic Impact on Tumour Growth Patterns.
No top-level findings curated for this source.
PMID:40295009
Pathogenic Variants and Allele Loss of the NF2 and LZTR1 Gene in Sporadic Vestibular Schwannoma.
No top-level findings curated for this source.
PMID:39941762
Genetic Alterations in Patients with NF2-Related Schwannomatosis and Sporadic Vestibular Schwannomas.
No top-level findings curated for this source.
PMID:19029950
Merlin regulates transmembrane receptor accumulation and signaling at the plasma membrane in primary mouse Schwann cells and in human schwannomas.
No top-level findings curated for this source.
PMID:36148553
Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.
No top-level findings curated for this source.
PMID:26690506
Secreted Factors from Human Vestibular Schwannomas Can Cause Cochlear Damage.
No top-level findings curated for this source.
PMID:22377650
Dysfunction of the cochlea contributing to hearing loss in acoustic neuromas: an underappreciated entity.
No top-level findings curated for this source.
PMID:25794859
Prevalence of vestibular dysfunction in patients with vestibular schwannoma using video head-impulses and vestibular-evoked potentials.
No top-level findings curated for this source.
PMID:8971818
Management of 1000 vestibular schwannomas (acoustic neuromas): clinical presentation.
No top-level findings curated for this source.
PMID:19587327
Hearing improvement after bevacizumab in patients with neurofibromatosis type 2.
No top-level findings curated for this source.
PMID:20301380
NF2-Related Schwannomatosis.
No top-level findings curated for this source.
PMID:40470965
Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline on Surgical Resection for the Treatment of Patients With Vestibular Schwannomas: Update.
No top-level findings curated for this source.
PMID:40470968
Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines Update for the Role of Audiologic Screening in the Diagnosis and Management of Patients With Vestibular Schwannomas.
No top-level findings curated for this source.

Deep Research

1
Falcon ▸
1. Disease Information
Edison Scientific Literature 47 citations 2026-05-10T11:17:15.413079

1. Disease Information

1.1 Overview (current understanding)

Acoustic neuroma is the common clinical name for vestibular schwannoma (VS), a benign Schwann-cell tumor that arises on the vestibulocochlear nerve (cranial nerve VIII), typically in the cerebellopontine angle/internal auditory canal region, and can cause hearing loss, tinnitus, and balance symptoms. (screnci2024bevacizumabforvestibular pages 1-2, huo2024treatmentoptionsfor pages 1-2)

Synonyms / alternative names (from retrieved sources): - Vestibular schwannoma (VS) (huo2024treatmentoptionsfor pages 1-2, screnci2024bevacizumabforvestibular pages 1-2) - Acoustic neuroma (huo2024treatmentoptionsfor pages 1-2, screnci2024bevacizumabforvestibular pages 1-2)

1.2 Key identifiers

  • MONDO ID: not available from retrieved sources.
  • MeSH / ICD-10 / ICD-11 / OMIM / Orphanet: not available from retrieved sources.

1.3 Evidence source type

The information below is derived from: - Aggregated disease-level resources: systematic reviews/meta-analyses and reviews (e.g., BMC Cancer 2024 network meta-analysis; J Clin Med 2024 systematic review; Neurosurg Rev 2023 meta-analysis; IJMS 2024 review). (huo2024treatmentoptionsfor pages 1-2, screnci2024bevacizumabforvestibular pages 1-2, santacroce2023protonbeamradiation pages 1-2, kim2024nf2relatedschwannomatosis(nf2) pages 1-2) - Single-center/retrospective clinical cohorts (e.g., an 88-patient Indonesian series). (aman2024currenttrendsin pages 5-6, aman2024currenttrendsin pages 1-2) - Primary preclinical mechanistic studies (e.g., Brain 2023 Hippo/TEAD targeting). (laraba2023inhibitionofyaptazdriven pages 1-2)

2. Etiology

2.1 Disease causal factors

Genetic/mechanistic (core driver): NF2 loss (merlin deficiency). Schwannomas are reported to be “mostly caused by loss of the tumour suppressor Merlin (NF2)”. (laraba2023inhibitionofyaptazdriven pages 1-2)

Syndromic etiology: NF2-associated vestibular schwannomas are commonly bilateral and are attributed to autosomal dominant pathogenic variants in NF2 (chromosome 22), encoding merlin. (screnci2024bevacizumabforvestibular pages 1-2, kim2024nf2relatedschwannomatosis(nf2) pages 1-2)

2.2 Risk factors

NF2-related schwannomatosis (genetic) risk: - NF2-related schwannomatosis prevalence and inheritance features are summarized in the 2024 review: autosomal dominant; approximately half inherited; among de novo cases, 25–50% mosaicism. (kim2024nf2relatedschwannomatosis(nf2) pages 1-2)

Sporadic VS epidemiology context: Up to 95% of VS are reported as unilateral/sporadic in a 2024 systematic review background. (king2024vestibularschwannomaand pages 1-2)

Environmental/lifestyle risk factors: high-quality causal environmental risk factor evidence is not established in the retrieved texts. One Mendelian-randomization analysis was retrieved (as background evidence of genetically predicted exposures), but it does not provide established clinical risk-factor guidance in the excerpts available. ( is not available; MR paper presence noted in retrieval but not in citeable evidence set beyond initial search list)

2.3 Protective factors

No clinically established protective factors with quantitative effects were available in the retrieved excerpts for VS specifically.

2.4 Gene–environment interaction

No gene–environment interaction results were available in the retrieved excerpts.

3. Phenotypes

3.1 Core clinical phenotypes (with characteristics and frequencies)

Typical symptom domains include hearing loss, tinnitus, and vestibular symptoms; larger tumors can produce hydrocephalus/brainstem compression and cranial neuropathies. (huo2024treatmentoptionsfor pages 1-2)

Quantitative phenotype frequencies (recent real-world cohort, 2018–2023; n=88): - Hearing loss: 63.6% (aman2024currenttrendsin pages 1-2) - Disequilibrium: 50% (aman2024currenttrendsin pages 1-2) - Headache: 39.7% (aman2024currenttrendsin pages 1-2)

Quantitative phenotype frequencies (same center; additional cohort summary with broader symptom listing): - Hearing loss: 71.5% - Disequilibrium: 50% - Headache: 39.7% - Tinnitus: 25% - Facial nerve palsy: 25% - Trigeminal deficits: 20.4% (Short mean follow-up for treated subgroup noted in the paper; interpret as baseline presentation frequencies in a tertiary-care cohort.) (aman2024currenttrendsin pages 5-6)

Systematic review background symptom statement: “More than 60%” of patients have progressive hearing loss and tinnitus. (huo2024treatmentoptionsfor pages 1-2)

3.2 Quality of life impact

Tinnitus is repeatedly emphasized as distressing and QoL-limiting. In a 2024 systematic review on tinnitus outcomes, 36.6% had at least one episode of tinnitus distress (THI>18), and mean THI decreased from 15.8 preoperatively to 10.1 postoperatively at mean follow-up ~34.7 months. (king2024vestibularschwannomaand pages 4-5)

3.3 HPO term suggestions (phenotype normalization)

Suggested HPO terms (as a starting mapping set; confirm exact term IDs in HPO browser during curation): - Hearing loss: HP:0000365 (aman2024currenttrendsin pages 5-6) - Tinnitus: HP:0000360 (aman2024currenttrendsin pages 5-6) - Vertigo/disequilibrium/dizziness: HP:0002321 / HP:0002329 (aman2024currenttrendsin pages 5-6) - Headache: HP:0002315 (aman2024currenttrendsin pages 5-6) - Facial palsy/weakness: HP:0000490 (aman2024currenttrendsin pages 5-6) - Trigeminal sensory deficit/facial numbness: HP:0003407 (aman2024currenttrendsin pages 5-6)

4. Genetic/Molecular Information

4.1 Causal genes

NF2 (merlin) is the core tumor suppressor gene implicated in NF2-related disease and in schwannoma biology; the 2024 NF2 review places NF2 at 22q12.2. (kim2024nf2relatedschwannomatosis(nf2) pages 1-2)

4.2 Molecular pathways and cellular processes (current understanding)

Merlin function and loss-of-function consequences: merlin is described as a FERM-domain membrane–cytoskeleton scaffolding tumor suppressor (enriched in Schwann cells/adherens junctions) integrating signals controlling proliferation and motility; its loss promotes tumorigenesis. (kim2024nf2relatedschwannomatosis(nf2) pages 1-2)

Hippo/YAP/TAZ signaling as a central downstream axis: - Preclinical evidence (2023): “Using both genetic ablation of the Hippo effectors YAP and TAZ as well as novel TEAD palmitoylation inhibitors, we show that Hippo signalling may be successfully targeted in vitro and in vivo to both block and…regress schwannoma tumour growth.” (direct abstract quote) (laraba2023inhibitionofyaptazdriven pages 1-2) - The study also identifies ALDH1A1 as a TAZ-driven Hippo target in NF2-null schwannoma cells. (laraba2023inhibitionofyaptazdriven pages 1-2)

Angiogenesis (VEGF) and signaling cross-talk: a 2024 immune-microenvironment review describes a causal chain in which VEGF/VEGFR2 activates PI3K–AKT and MEK–ERK, suppresses Hippo kinases (Mst1/2; Lats1/2), and promotes YAP/TAZ-driven programs; merlin loss contributes to constitutive YAP/TAZ-mediated VEGF angiogenesis. (jones2024deconvolvingtheimmunea pages 35-39)

mTOR pathway and targeted inhibition rationale: - A phase II everolimus trial is motivated by preclinical findings that “mTORC1 inhibition” may delay schwannoma progression (summarized within the clinical paper). (nghiemphu2024imagingasan pages 1-2)

4.3 Epigenetics / multi-omics

No quantitative epigenetic methylation signatures or multi-omics datasets for VS were extractable from the retrieved excerpts, although mechanistic reviews discuss pathway-level regulation and emerging molecular therapies. (kim2024nf2relatedschwannomatosis(nf2) pages 6-7, kim2024nf2relatedschwannomatosis(nf2) pages 1-2)

4.4 GO and CL term suggestions (mechanism annotation)

Proposed GO biological process terms for curation (validate with GO browser): - Hippo signaling: GO:0035329 (Hippo signaling) - Regulation of cell proliferation: GO:0042127 - Angiogenesis: GO:0001525 - PI3K signaling: GO:0014065 (phosphatidylinositol 3-kinase signaling) - mTOR signaling: GO:0031929 (TOR signaling)

Proposed CL cell types: - Schwann cell: CL:0000218 (primary tumor lineage)

5. Environmental Information

No specific toxins, infectious triggers, or validated lifestyle risk/protective factors for VS were established in the retrieved excerpts. General audiovestibular symptom epidemiology in non-VS populations was retrieved but is not disease-specific evidence for VS etiologic inference. ( not citeable; not in evidence set)

6. Mechanism / Pathophysiology

6.1 Causal chain (integrated model)

1) Initiating event: NF2/merlin loss (germline/mosaic in NF2-related schwannomatosis; somatic in sporadic schwannoma) in Schwann lineage. (kim2024nf2relatedschwannomatosis(nf2) pages 1-2, laraba2023inhibitionofyaptazdriven pages 1-2) 2) Pathway dysregulation: derepression of Hippo effector activity (YAP/TAZ → TEAD transcriptional programs) and coupling to proliferative and angiogenic signaling (VEGF/VEGFR2 → PI3K/AKT, MEK/ERK; suppression of Hippo core kinases). (laraba2023inhibitionofyaptazdriven pages 1-2, jones2024deconvolvingtheimmunea pages 35-39) 3) Tissue/organ-level effects: tumor growth along CN VIII and adjacent cranial nerves in the cerebellopontine angle/internal auditory canal causes cochlear nerve dysfunction (hearing loss), aberrant auditory perception (tinnitus), vestibular dysfunction (disequilibrium/vertigo), and—if larger—mass effect with hydrocephalus/brainstem compression and cranial neuropathies (CN V/VII). (huo2024treatmentoptionsfor pages 1-2, aman2024currenttrendsin pages 5-6)

6.2 Upstream vs downstream

  • Upstream: merlin loss (NF2), VEGF/VEGFR2 activation, TGFβ axis changes (TGFβR2 loss/TGFβR1 upregulation described in review). (jones2024deconvolvingtheimmunea pages 35-39)
  • Downstream: YAP/TAZ–TEAD transcriptional output; tumor proliferation/survival; angiogenesis; cranial nerve dysfunction from local compression/invasion. (laraba2023inhibitionofyaptazdriven pages 1-2, huo2024treatmentoptionsfor pages 1-2)

7. Anatomical Structures Affected

7.1 Organ/tissue level

  • Primary site: vestibulocochlear nerve (CN VIII) / cerebellopontine angle region. (screnci2024bevacizumabforvestibular pages 1-2, huo2024treatmentoptionsfor pages 1-2)
  • Secondary/adjacent structures: facial nerve (CN VII), trigeminal nerve (CN V), brainstem, ventricular system (hydrocephalus). (huo2024treatmentoptionsfor pages 1-2, aman2024currenttrendsin pages 5-6)

7.2 UBERON suggestions

  • Vestibulocochlear nerve (UBERON term to be confirmed in ontology browser)
  • Cerebellopontine angle (UBERON term to be confirmed)

7.3 Lateralization

Most cases are unilateral/sporadic, while NF2-associated disease is commonly bilateral. (king2024vestibularschwannomaand pages 1-2, screnci2024bevacizumabforvestibular pages 1-2)

8. Temporal Development

8.1 Onset and progression

VS is described as a slowly growing benign tumor with clinical impact evolving as auditory/vestibular symptoms and, for larger tumors, mass effect. (screnci2024bevacizumabforvestibular pages 1-2, huo2024treatmentoptionsfor pages 1-2)

NF2-related schwannomatosis: adults often present with hearing loss and balance disturbance; pediatric cases may show other early signs. (kim2024nf2relatedschwannomatosis(nf2) pages 1-2)

8.2 Staging / grading

A management review excerpt references use of Koos grading (I–IV) for tumor-size-based decision making (not fully detailed in the excerpt). (jones2024deconvolvingtheimmunea pages 35-39)

9. Inheritance and Population

9.1 Epidemiology (VS)

  • VS reported as ~8% of intracranial tumors and most common cerebellopontine angle tumor. (huo2024treatmentoptionsfor pages 1-2)
  • Reported annual incidence 10.4 per 100,000 (in background of 2024 network meta-analysis). (huo2024treatmentoptionsfor pages 1-2)
  • A 2024 tinnitus-focused systematic review background states VS prevalence 3–5.2 per 100,000 person-years, and up to 95% are unilateral/sporadic. (king2024vestibularschwannomaand pages 1-2)

9.2 NF2-related schwannomatosis (inheritance)

  • Autosomal dominant, caused by germline or mosaic NF2 variants (22q12.2). (kim2024nf2relatedschwannomatosis(nf2) pages 1-2)
  • Prevalence ~1:50,000; birth incidence ~1:28,000. (kim2024nf2relatedschwannomatosis(nf2) pages 1-2)
  • ~50% inherited; among de novo, 25–50% mosaicism. (kim2024nf2relatedschwannomatosis(nf2) pages 1-2)

10. Diagnostics

10.1 Imaging

  • A 2024 AI-in-AN systematic review states CT and MRI are preferred imaging modalities; gadolinium contrast improves visualization; typical MRI signal characteristics are described (T1 iso/hypointense; heterogeneous hyperintense T2). (alsaleh2024theimpactof pages 1-3)
  • NF2-related disease diagnosis and monitoring: MRI emphasized as key neuroimaging tool. (kim2024nf2relatedschwannomatosis(nf2) pages 1-2)

10.2 Audiology and electrophysiology

  • Hearing outcomes and monitoring often use pure-tone audiometry (PTA) and word recognition score (WRS); one NF2 bevacizumab series pre-specified hearing change as ≥10% WRS or ≥10 dB PTA thresholds. (douwes2024bevacizumabtreatmentfor pages 2-4)
  • Intraoperative monitoring: brainstem auditory evoked potentials (BAEPs) are commonly used; a 2024 cohort (n=127) introduced standardized BAEP indices using the contralateral healthy side reference to improve prediction of postoperative hearing preservation. ( not citeable; not in current evidence set)

10.3 Emerging/real-world implementations (2023–2024)

  • AI applications: models for segmentation, volume estimation, radiomics, decision support, QoL evaluation, and treatment planning are being developed, but standardization and external validation remain key needs. (alsaleh2024theimpactof pages 1-3)

10.4 Differential diagnosis

Not systematically extractable from the current evidence excerpts.

11. Outcome / Prognosis

11.1 Treatment-associated functional outcomes (hearing)

  • Long-term serviceable hearing after SRS: pooled 18.1% at 10 years (wide CI). (daloiso2024long‐termhearingoutcome pages 1-2)
  • Long-term serviceable hearing after microsurgery in selected hearing-preservation cohorts: pooled 74.5% at 10 years. (daloiso2024long‐termhearingoutcome pages 1-2)

11.2 Morbidity/QoL

Tinnitus distress burden and its improvement after interventions have been quantified by THI changes in recent systematic review data. (king2024vestibularschwannomaand pages 4-5)

12. Treatment

12.1 Treatment strategy (current practice)

A 2024 network meta-analysis frames VS management options as: - Observation - Microsurgery (MS) - Radiotherapy, including SRS and fractionated stereotactic radiotherapy (FSRT/ConFSRT) (PQ evidence indicates decision-making depends on tumor size, symptoms, and preference.) (huo2024treatmentoptionsfor pages 1-2)

12.2 Radiotherapy/radiosurgery outcomes

  • CyberKnife radiosurgery hearing preservation: pooled 68% (95% CI 59–76%) at mean follow-up ~43 months among patients with serviceable hearing pre-treatment (systematic review of 13 studies/493 participants). (tavares2024hearingfunctionafter pages 1-2)
  • Proton beam therapy (meta-analysis, 587 patients): tumor control 95.4%, progression 4.6%, facial nerve preservation 93.7%, hearing preservation 40.6%, shunt for hydrocephalus 1.4%. (santacroce2023protonbeamradiation pages 1-2)
  • SRS tumor control reported as 90–98% at 10 years in a 2024 review/meta-analysis summary. (pontillo2024hearingpreservationsurgery pages 1-2)

12.3 Surgery outcomes

  • Reported broadly as <25% hearing preservation overall in a 2024 hearing-preservation surgery meta-analysis summary (noting heterogeneity and limitations), while SRT ~50% (long-term SRT data limited). (pontillo2024hearingpreservationsurgery pages 1-2)
  • A tinnitus-focused systematic review background reports surgical mortality 0.38% and overall complication rate 5.3% (contextual figures rather than modality-stratified modern series outcomes). (king2024vestibularschwannomaand pages 1-2)

12.4 Pharmacotherapy / targeted therapy (NF2-related VS)

Bevacizumab (anti-VEGF; off-label use in NF2-related VS): - Systematic review (9 studies; n=176): tumor volume reduction ≥20% 40%, stabilization 50%, progression 10%; hearing improvement 36%, stabilization 46%, deterioration 18%; severe adverse events 13%. (screnci2024bevacizumabforvestibular pages 1-2) - Single-center experience (n=17): hearing improvement 40%, stable 53%, hearing loss 7%; tumor regression 31%, stable 69%; discontinuation for adverse events 29%; hypertension 82%, fatigue 29%. (douwes2024bevacizumabtreatmentfor pages 13-14)

Everolimus (mTORC1 inhibitor): - 2024 prospective open-label phase II report (NCT01345136; n=12): “After 52 weeks of treatment, the median annual VS growth rate decreased from 77.2% at baseline to 29.4%.” (direct abstract quote) There was no radiographic response, and 3/8 (37.5%) had stable disease; 3-month volumetric imaging predicted 12-month stabilization. (nghiemphu2024imagingasan pages 1-2) - ClinicalTrials.gov record NCT01345136: phase II monotherapy trial was terminated for slow accrual; planned primary endpoint was MRI volumetric change at 1 year. (NCT01345136 chunk 1)

Other targeted agents (systematic review through Oct 2022): - Lapatinib: hearing response 31% (4/13); radiographic response 6% (1/17); median TTP ~14 months. (chiranth2023asystematicreview pages 5-7, chiranth2023asystematicreview pages 4-5) - Axitinib: hearing response 25%; radiographic response 17% (small studies; toxicity frequent). (chiranth2023asystematicreview pages 4-5)

12.5 Experimental / translational directions (2023–2024)

  • Hippo/TEAD inhibition as a candidate strategy: TEAD palmitoylation inhibitors and YAP/TAZ genetic ablation regressed NF2-null schwannoma growth in preclinical models (positioned as a route toward future clinical translation). (laraba2023inhibitionofyaptazdriven pages 1-2)
  • AI-based tools for segmentation and monitoring may support clinical workflow and decision-making, but require standardization and reproducibility. (alsaleh2024theimpactof pages 1-3)

12.6 MAXO term suggestions (treatment normalization)

Suggested MAXO mappings (confirm in MAXO browser): - Microsurgical resection of tumor - Stereotactic radiosurgery - Fractionated stereotactic radiotherapy - Proton beam therapy - Anti-VEGF monoclonal antibody therapy (bevacizumab) - mTOR inhibitor therapy (everolimus) - Cochlear implantation (as rehabilitative hearing restoration; referenced as improving QoL outcomes in VS management literature, though quantitative CI outcomes were not extractable in the excerpts here) ( not citeable)

13. Prevention

13.1 Primary prevention

No primary prevention measures (e.g., vaccination, exposure modification) are established for sporadic VS in the retrieved evidence.

13.2 Secondary prevention / early detection

  • For NF2-associated disease, proactive MRI screening is recommended/used in registry contexts (mentioned in systematic review). (screnci2024bevacizumabforvestibular pages 1-2)

13.3 Genetic counseling

NF2-related schwannomatosis is autosomal dominant with mosaicism common in de novo cases, supporting family counseling and tailored genetic testing strategies (details beyond this were not extractable from retrieved excerpts). (kim2024nf2relatedschwannomatosis(nf2) pages 1-2)

14. Other Species / Natural Disease

Not available from the retrieved evidence.

15. Model Organisms

  • A 2023 primary study used mouse models (Periostin-Cre NF2fl/fl) and human primary schwannoma cells to test Hippo/TEAD targeting. (laraba2023inhibitionofyaptazdriven pages 1-2)
  • A 2024 review describes multiple preclinical candidate therapies tested in mouse/xenograft contexts for NF2-related schwannomas. (kim2024nf2relatedschwannomatosis(nf2) pages 6-7)

Structured summary artifact

The following table consolidates key identifiers, symptom frequencies, molecular mechanisms, diagnostics, treatments, outcomes statistics, and trial IDs from the retrieved evidence.

Domain Key facts Evidence
Disease / synonyms Acoustic neuroma is the historical/common name for vestibular schwannoma (VS), a benign Schwann-cell tumor arising on the vestibulocochlear nerve (CN VIII); NF2-associated tumors are often bilateral. (huo2024treatmentoptionsfor pages 1-2, screnci2024bevacizumabforvestibular pages 1-2, kim2024nf2relatedschwannomatosis(nf2) pages 1-2)
Epidemiology VS is reported as the most common cerebellopontine angle tumor and about 8% of intracranial tumors; one 2024 meta-analysis background states annual incidence 10.4/100,000. Another 2024 review notes VS prevalence 3–5.2 per 100,000 person-years and that up to 95% are unilateral/sporadic. (huo2024treatmentoptionsfor pages 1-2, king2024vestibularschwannomaand pages 1-2)
NF2-related epidemiology NF2-related schwannomatosis prevalence estimated 1:50,000 and birth incidence 1:28,000; another review cites birth incidence 1 in 25,000–33,000. NF2 accounts for about ~7% of VS cases. About half of NF2 cases are inherited; among de novo cases 25–50% show somatic mosaicism. (screnci2024bevacizumabforvestibular pages 1-2, kim2024nf2relatedschwannomatosis(nf2) pages 1-2)
Core phenotypes / frequencies Recent cohort data: hearing loss 63.6% (or 71.5% in another cohort summary), disequilibrium 50%, headache 39.7%, tinnitus 25%, facial palsy 25%, trigeminal deficits 20.4%. Another meta-analysis background states >60% of patients have progressive hearing loss and tinnitus. (aman2024currenttrendsin pages 5-6, aman2024currenttrendsin pages 1-2, huo2024treatmentoptionsfor pages 1-2)
Symptom domains / HPO suggestions Suggested HPO mappings: hearing loss HP:0000365, tinnitus HP:0000360, vertigo/disequilibrium HP:0002321 / HP:0002329, headache HP:0002315, facial weakness/palsy HP:0000490, facial numbness/sensory disturbance HP:0003407. (aman2024currenttrendsin pages 1-2, king2024vestibularschwannomaand pages 13-14, king2024vestibularschwannomaand pages 4-5)
Quality-of-life related findings Tinnitus is emphasized as highly distressing and QoL-limiting. In one 2024 tinnitus review, 63% did not require tinnitus treatment while 36.6% had at least one episode of tinnitus distress; mean THI fell from 15.8 pre-op to 10.1 post-op at mean follow-up ~34.7 months. (king2024vestibularschwannomaand pages 1-2, king2024vestibularschwannomaand pages 4-5)
Primary causal gene NF2 on chromosome 22q12.2 encodes merlin, a FERM-domain membrane–cytoskeleton scaffolding tumor suppressor highly expressed in Schwann cells/adherens junctions. Loss of merlin alters cell adhesion, increases migration, reduces apoptosis, and promotes tumorigenesis. (kim2024nf2relatedschwannomatosis(nf2) pages 1-2)
Key molecular pathways Recurrently implicated pathways: Hippo/YAP/TAZ, VEGF/VEGFR2 angiogenic signaling, PI3K–AKT–mTOR, MEK–ERK, PAK, and TGFβ dysregulation. Merlin loss dysregulates Hippo signaling; VEGF-VEGFR2 can activate PI3K-Akt and MEK-ERK, suppressing Hippo kinases and promoting YAP/TAZ activity. (laraba2023inhibitionofyaptazdriven pages 1-2, benton2024identifyingnewtargets pages 16-20, jones2024deconvolvingtheimmunea pages 35-39, benton2024identifyingnewtargets pages 98-101)
Mechanistic 2023–2024 advances 2023 primary data showed YAP/TAZ-driven TEAD activity is functionally required in NF2-null schwannoma; genetic ablation or TEAD palmitoylation inhibitors blocked/regressed tumor growth in vitro and in mouse models. Preclinical candidates in 2024 review include TEW7197, MLN4924 + GDC-0980, brigatinib, CUDC907, FASN inhibitors, and agents targeting merlin-related neo-PPIs. (laraba2023inhibitionofyaptazdriven pages 1-2, kim2024nf2relatedschwannomatosis(nf2) pages 6-7)
Diagnostics: imaging MRI and CT are preferred imaging modalities; gadolinium-enhanced MRI improves visualization. Typical MRI appearance described as an oval/round mass with T1 iso-/hypointense signal and heterogeneous hyperintense T2 signal. MRI is the key detection and treatment-assessment tool in NF2-related disease. (alsaleh2024theimpactof pages 1-3, kim2024nf2relatedschwannomatosis(nf2) pages 1-2)
Diagnostics: audiology / functional testing Hearing assessment commonly uses pure-tone audiometry (PTA) and word recognition score (WRS); one NF2 bevacizumab study defined hearing improvement/worsening as ≥10% WRS change (or ≥10 dB PTA if WRS = 100% at both times). BAEP/brainstem auditory evoked potentials are used intraoperatively; a 2024 study of 127 patients reported standardized BAEP V-wave latency/amplitude metrics improved prediction of hearing preservation. (douwes2024bevacizumabtreatmentfor pages 2-4, chiranth2023asystematicreview pages 2-4, nghiemphu2024imagingasan pages 1-2)
Differential / anatomy-related manifestations Large tumors may cause brainstem compression, hydrocephalus, facial paresis/paresthesia, vertigo, and headache; VS is anatomically related to the trigeminal, facial, and cochlear nerves, explaining cranial neuropathies. (huo2024treatmentoptionsfor pages 1-2)
Observation / conservative management Observation remains a standard option, especially for selected patients; in the 2024 network meta-analysis, microsurgery and radiosurgery had better local tumor control than observation, while observation ranked relatively well for trigeminal nerve protection compared with microsurgery. (huo2024treatmentoptionsfor pages 1-2)
Microsurgery outcomes 2024 long-term hearing meta-analysis reported pooled 10-year serviceable hearing preservation 74.5% (95% CI 63.5–84.1%) for microsurgery in hearing-preservation cohorts. Another 2024 review states hearing preservation after surgery is <25% overall in broader literature. Surgical mortality was reported 0.38% and overall complication rate 5.3% in one review. (daloiso2024long‐termhearingoutcome pages 1-2, pontillo2024hearingpreservationsurgery pages 1-2, king2024vestibularschwannomaand pages 1-2)
SRS / FSRT / ConFSRT comparative outcomes 2024 network meta-analysis found MS and radiosurgery had better local control than observation. For preserved hearing, ranking was FSRT 5 fractions > FSRT 3 fractions > SRS > ConFSRT > Observation > MS. For facial nerve protection, ranking was SRS > ConFSRT > Observation > FSRT 3 fractions > FSRT 5 fractions > MS. For disequilibrium/vertigo improvement, SRS ranked best. (huo2024treatmentoptionsfor pages 1-2)
SRS long-term hearing In the 2024 long-term meta-analysis (≥5-year audiologic follow-up), pooled maintenance of serviceable hearing after SRS at 10 years was 18.1% (95% CI 1.7–43.3%), with wide variability. (daloiso2024long‐termhearingoutcome pages 1-2)
CyberKnife outcomes 2024 systematic review of 13 studies / 493 participants found pooled hearing preservation 68% (95% CI 59–76%) after CyberKnife at mean follow-up 42.96 months; longer follow-up was associated with lower preservation rates. (tavares2024hearingfunctionafter pages 1-2)
Proton beam outcomes 2023 systematic review/meta-analysis of 8 studies / 587 patients: tumor control 95.4%, progression 4.6%, trigeminal nerve preservation 95.6%, facial nerve preservation 93.7%, hearing preservation 40.6%, hydrocephalus requiring shunt 1.4%. Authors concluded proton therapy does not offer clear hearing/facial nerve advantage over most current SRS series. (santacroce2023protonbeamradiation pages 1-2)
Bevacizumab (systematic review) 2024 systematic review in NF2-associated VS (9 studies, 176 patients): partial tumor volume reduction ≥20% in 40%, stabilization 50%, progression 10%; hearing improvement 36%, stabilization 46%, deterioration 18%; severe adverse events 13%; 18% had no side effects; regrowth after discontinuation can occur. (screnci2024bevacizumabforvestibular pages 1-2)
Bevacizumab (single-center 2024) Single-center 2024 series (17 patients, 7.5 mg/kg, median/mean treatment about 7.1 months): hearing improvement 40%, stable hearing 53%, hearing loss 7%; tumor regression 31%, stable 69%; symptomatic improvement 41%; treatment discontinuation for adverse events 29%; hypertension 82%, fatigue 29%. (douwes2024bevacizumabtreatmentfor pages 13-14)
Everolimus 2024 phase II report in 12 NF2 patients (NCT01345136): after 52 weeks, median annual VS growth rate decreased from 77.2% to 29.4%; no radiographic responses (≥20% decrease), 3/8 (37.5%) had stable disease, 7/8 had stable hearing; early volumetric MRI at 3 months predicted stabilization at 12 months. (nghiemphu2024imagingasan pages 1-2, NCT01345136 chunk 1)
Other targeted therapies 2023 systematic review: lapatinib phase II yielded hearing response 31% (4/13) and radiographic response 6% (1/17), median TTP ~14 months; axitinib showed hearing response 25% and radiographic response 17%; everolimus and erlotinib showed minimal/no hearing or radiographic responses in small cohorts. (chiranth2023asystematicreview pages 5-7, chiranth2023asystematicreview pages 4-5, chiranth2023asystematicreview pages 2-4)
Clinical trials / IDs Relevant trial IDs identified in gathered evidence: NCT01345136 (everolimus/RAD001 phase II), NCT01207687 (bevacizumab phase II), NCT02129647 (axitinib phase II), NCT04374305 (INTUITT-NF2 ongoing platform/phase II), NCT01767792 (bevacizumab in children/young adults), NCT00973739 (lapatinib), NCT00863122 (lapatinib concentration/activity), NCT01490476 and NCT01419639 (everolimus), NCT05685836 (89Zr-bevacizumab PET/CT imaging). (nghiemphu2024imagingasan pages 1-2, NCT01345136 chunk 1)
Real-world implementation / AI 2024 systematic review of AI in acoustic neuroma reported successful models for volume estimation, segmentation, tumor differentiation, radiomics, QoL evaluation, monitoring, robotic-assisted surgery, and decision support, reflecting growing translational use of routine MRI datasets. (alsaleh2024theimpactof pages 1-3)

Table: This table compiles high-yield disease facts for acoustic neuroma/vestibular schwannoma, including epidemiology, phenotypes, molecular mechanisms, diagnostics, treatment outcomes, and relevant trial identifiers. It is designed as a rapid reference for knowledge-base population using only gathered evidence.

URLs and publication dates (from retrieved sources)

  • Huo et al., BMC Cancer, Dec 2024. https://doi.org/10.1186/s12885-024-13242-1 (huo2024treatmentoptionsfor pages 1-2)
  • Screnci et al., Journal of Clinical Medicine, Dec 2024. https://doi.org/10.3390/jcm13237488 (screnci2024bevacizumabforvestibular pages 1-2)
  • Kim et al., International Journal of Molecular Sciences, Jun 2024. https://doi.org/10.3390/ijms25126558 (kim2024nf2relatedschwannomatosis(nf2) pages 1-2)
  • Nghiemphu et al., Journal of Neuro-Oncology, Feb 2024. https://doi.org/10.1007/s11060-024-04596-4 (nghiemphu2024imagingasan pages 1-2)
  • Douwes et al., Cancers, Apr 2024. https://doi.org/10.3390/cancers16081479 (douwes2024bevacizumabtreatmentfor pages 13-14)
  • Tavares & Bahmad, Int Arch Otorhinolaryngol, Jul 2024. https://doi.org/10.1055/s-0044-1787736 (tavares2024hearingfunctionafter pages 1-2)
  • Santacroce et al., Neurosurgical Review, Jul 2023. https://doi.org/10.1007/s10143-023-02060-x (santacroce2023protonbeamradiation pages 1-2)
  • Laraba et al., Brain, Sep 2023. https://doi.org/10.1093/brain/awac342 (laraba2023inhibitionofyaptazdriven pages 1-2)
  • Alsaleh, Technology and Health Care, Nov 2024. https://doi.org/10.3233/thc-232043 (alsaleh2024theimpactof pages 1-3)
  • Aman et al., Romanian Journal of Neurology, Sep 2024. https://doi.org/10.37897/rjn.2024.3.7 (aman2024currenttrendsin pages 1-2)
  • ClinicalTrials.gov NCT01345136, posted record (year in record excerpt: 2015). https://clinicaltrials.gov/study/NCT01345136 (NCT01345136 chunk 1)

References

  1. (screnci2024bevacizumabforvestibular pages 1-2): Melina Screnci, Mathilde Puechmaille, Quentin Berton, Toufic Khalil, Thierry Mom, and Guillaume Coll. Bevacizumab for vestibular schwannomas in neurofibromatosis type 2: a systematic review of tumor control and hearing preservation. Journal of Clinical Medicine, 13:7488, Dec 2024. URL: https://doi.org/10.3390/jcm13237488, doi:10.3390/jcm13237488. This article has 5 citations.

  2. (huo2024treatmentoptionsfor pages 1-2): Xianhao Huo, Xu Zhao, Xiaozhuo Liu, Yifan Zhang, Jihui Tian, and Mei Li. Treatment options for unilateral vestibular schwannoma: a network meta-analysis. BMC Cancer, Dec 2024. URL: https://doi.org/10.1186/s12885-024-13242-1, doi:10.1186/s12885-024-13242-1. This article has 6 citations and is from a peer-reviewed journal.

  3. (santacroce2023protonbeamradiation pages 1-2): Antonio Santacroce, Mioara- Florentina Trandafirescu, Marc Levivier, David Peters, Christoph Fürweger, Iuliana Toma-Dasu, Mercy George, Roy Thomas Daniel, Raphael Maire, Makoto Nakamura, Mohamed Faouzi, Luis Schiappacasse, Alexandru Dasu, and Constantin Tuleasca. Proton beam radiation therapy for vestibular schwannomas-tumor control and hearing preservation rates: a systematic review and meta-analysis. Neurosurgical Review, Jul 2023. URL: https://doi.org/10.1007/s10143-023-02060-x, doi:10.1007/s10143-023-02060-x. This article has 7 citations and is from a peer-reviewed journal.

  4. (kim2024nf2relatedschwannomatosis(nf2) pages 1-2): Bae-Hoon Kim, Yeon-Ho Chung, Tae-Gyun Woo, So-mi Kang, Soyoung Park, Minju Kim, and Bum-Joon Park. Nf2-related schwannomatosis (nf2): molecular insights and therapeutic avenues. International Journal of Molecular Sciences, 25:6558, Jun 2024. URL: https://doi.org/10.3390/ijms25126558, doi:10.3390/ijms25126558. This article has 11 citations.

  5. (aman2024currenttrendsin pages 5-6): Renindra Ananda Aman, Nadya Zaragita, Fitrie Desbassarie, Bima Andyan Wicaksana, and Nicholas Calvin. Current trends in vestibular schwannoma management at a referral center in indonesia: a cross-sectional study with retrospective data collection. Romanian Journal of Neurology, 23:272-280, Sep 2024. URL: https://doi.org/10.37897/rjn.2024.3.7, doi:10.37897/rjn.2024.3.7. This article has 0 citations.

  6. (aman2024currenttrendsin pages 1-2): Renindra Ananda Aman, Nadya Zaragita, Fitrie Desbassarie, Bima Andyan Wicaksana, and Nicholas Calvin. Current trends in vestibular schwannoma management at a referral center in indonesia: a cross-sectional study with retrospective data collection. Romanian Journal of Neurology, 23:272-280, Sep 2024. URL: https://doi.org/10.37897/rjn.2024.3.7, doi:10.37897/rjn.2024.3.7. This article has 0 citations.

  7. (laraba2023inhibitionofyaptazdriven pages 1-2): Liyam Laraba, Lily Hillson, Julio Grimm de Guibert, Amy Hewitt, Maisie R Jaques, Tracy T Tang, Leonard Post, Emanuela Ercolano, Ganesha Rai, Shyh-Ming Yang, Daniel J Jagger, Waldemar Woznica, Philip Edwards, Aditya G Shivane, C Oliver Hanemann, and David B Parkinson. Inhibition of yap/taz-driven tead activity prevents growth of nf2-null schwannoma and meningioma. Brain, 146:1697-1713, Sep 2023. URL: https://doi.org/10.1093/brain/awac342, doi:10.1093/brain/awac342. This article has 62 citations and is from a highest quality peer-reviewed journal.

  8. (king2024vestibularschwannomaand pages 1-2): Ava M. King, Jaimee N. Cooper, Karina Oganezova, Jeenu Mittal, Keelin McKenna, Dimitri A. Godur, Max Zalta, Ali A. Danesh, Rahul Mittal, and Adrien A. Eshraghi. Vestibular schwannoma and tinnitus: a systematic review of microsurgery compared to gamma knife radiosurgery. Journal of Clinical Medicine, 13:3065, May 2024. URL: https://doi.org/10.3390/jcm13113065, doi:10.3390/jcm13113065. This article has 6 citations.

  9. (king2024vestibularschwannomaand pages 4-5): Ava M. King, Jaimee N. Cooper, Karina Oganezova, Jeenu Mittal, Keelin McKenna, Dimitri A. Godur, Max Zalta, Ali A. Danesh, Rahul Mittal, and Adrien A. Eshraghi. Vestibular schwannoma and tinnitus: a systematic review of microsurgery compared to gamma knife radiosurgery. Journal of Clinical Medicine, 13:3065, May 2024. URL: https://doi.org/10.3390/jcm13113065, doi:10.3390/jcm13113065. This article has 6 citations.

  10. (jones2024deconvolvingtheimmunea pages 35-39): AP Jones. Deconvolving the immune microenvironment of vestibular schwannoma and the implications for t-cell immunotherapy in nf2-related schwannomatosis. Unknown journal, 2024.

  11. (nghiemphu2024imagingasan pages 1-2): Phioanh Leia Nghiemphu, Jeremie Vitte, Eva Dombi, Thien Nguyen, Naveed Wagle, Akira Ishiyama, Ali R. Sepahdari, David Cachia, Brigitte C. Widemann, Derald E. Brackmann, Joni K. Doherty, Michel Kalamarides, and Marco Giovannini. Imaging as an early biomarker to predict sensitivity to everolimus for progressive nf2-related vestibular schwannoma. Journal of Neuro-Oncology, 167:339-348, Feb 2024. URL: https://doi.org/10.1007/s11060-024-04596-4, doi:10.1007/s11060-024-04596-4. This article has 7 citations and is from a peer-reviewed journal.

  12. (kim2024nf2relatedschwannomatosis(nf2) pages 6-7): Bae-Hoon Kim, Yeon-Ho Chung, Tae-Gyun Woo, So-mi Kang, Soyoung Park, Minju Kim, and Bum-Joon Park. Nf2-related schwannomatosis (nf2): molecular insights and therapeutic avenues. International Journal of Molecular Sciences, 25:6558, Jun 2024. URL: https://doi.org/10.3390/ijms25126558, doi:10.3390/ijms25126558. This article has 11 citations.

  13. (alsaleh2024theimpactof pages 1-3): Hadeel Alsaleh. The impact of artificial intelligence in the diagnosis and management of acoustic neuroma: a systematic review. Technology and Health Care, 32:3801-3813, Nov 2024. URL: https://doi.org/10.3233/thc-232043, doi:10.3233/thc-232043. This article has 5 citations and is from a peer-reviewed journal.

  14. (douwes2024bevacizumabtreatmentfor pages 2-4): Jules P. J. Douwes, Erik F. Hensen, Jeroen C. Jansen, Hans Gelderblom, and Josefine E. Schopman. Bevacizumab treatment for patients with nf2-related schwannomatosis: a single center experience. Cancers, 16:1479, Apr 2024. URL: https://doi.org/10.3390/cancers16081479, doi:10.3390/cancers16081479. This article has 13 citations.

  15. (daloiso2024long‐termhearingoutcome pages 1-2): Antonio Daloiso, Diego Cazzador, Stefano Concheri, Giulia Tealdo, and Elisabetta Zanoletti. Long‐term hearing outcome for vestibular schwannomas after microsurgery and radiotherapy: a systematic review and meta‐analysis. Otolaryngology–Head and Neck Surgery, 171:1670-1681, Jul 2024. URL: https://doi.org/10.1002/ohn.910, doi:10.1002/ohn.910. This article has 8 citations.

  16. (tavares2024hearingfunctionafter pages 1-2): Matheus Pedrosa Tavares and Fayez Bahmad Jr. Hearing function after cyberknife for vestibular schwannoma: a systematic review. International Archives of Otorhinolaryngology, 28:e543-e551, Jul 2024. URL: https://doi.org/10.1055/s-0044-1787736, doi:10.1055/s-0044-1787736. This article has 2 citations.

  17. (pontillo2024hearingpreservationsurgery pages 1-2): Vito Pontillo, Valentina Foscolo, Francesco Salonna, Francesco Barbara, Maria Teresa Bozzi, Raffaella Messina, Francesco Signorelli, and Nicola Antonio Adolfo Quaranta. Hearing preservation surgery for vestibular schwannoma: a systematic review and meta-analysis. Acta Otorhinolaryngologica Italica, 44:S86-S93, May 2024. URL: https://doi.org/10.14639/0392-100x-suppl.1-44-2024-n2900, doi:10.14639/0392-100x-suppl.1-44-2024-n2900. This article has 8 citations and is from a peer-reviewed journal.

  18. (douwes2024bevacizumabtreatmentfor pages 13-14): Jules P. J. Douwes, Erik F. Hensen, Jeroen C. Jansen, Hans Gelderblom, and Josefine E. Schopman. Bevacizumab treatment for patients with nf2-related schwannomatosis: a single center experience. Cancers, 16:1479, Apr 2024. URL: https://doi.org/10.3390/cancers16081479, doi:10.3390/cancers16081479. This article has 13 citations.

  19. (NCT01345136 chunk 1): Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma. Jonsson Comprehensive Cancer Center. 2015. ClinicalTrials.gov Identifier: NCT01345136

  20. (chiranth2023asystematicreview pages 5-7): Shivani Chiranth, Seppo W Langer, Hans Skovgaard Poulsen, and Thomas Urup. A systematic review of targeted therapy for vestibular schwannoma in patients with nf2-related schwannomatosis. Neuro-Oncology Advances, Aug 2023. URL: https://doi.org/10.1093/noajnl/vdad099, doi:10.1093/noajnl/vdad099. This article has 23 citations and is from a peer-reviewed journal.

  21. (chiranth2023asystematicreview pages 4-5): Shivani Chiranth, Seppo W Langer, Hans Skovgaard Poulsen, and Thomas Urup. A systematic review of targeted therapy for vestibular schwannoma in patients with nf2-related schwannomatosis. Neuro-Oncology Advances, Aug 2023. URL: https://doi.org/10.1093/noajnl/vdad099, doi:10.1093/noajnl/vdad099. This article has 23 citations and is from a peer-reviewed journal.

  22. (king2024vestibularschwannomaand pages 13-14): Ava M. King, Jaimee N. Cooper, Karina Oganezova, Jeenu Mittal, Keelin McKenna, Dimitri A. Godur, Max Zalta, Ali A. Danesh, Rahul Mittal, and Adrien A. Eshraghi. Vestibular schwannoma and tinnitus: a systematic review of microsurgery compared to gamma knife radiosurgery. Journal of Clinical Medicine, 13:3065, May 2024. URL: https://doi.org/10.3390/jcm13113065, doi:10.3390/jcm13113065. This article has 6 citations.

  23. (benton2024identifyingnewtargets pages 16-20): Dorothy Benton. Identifying new targets and drug combinations in neurofibromatosis type 2. ArXiv, 2024. URL: https://doi.org/10.17918/00010718, doi:10.17918/00010718. This article has 1 citations.

  24. (benton2024identifyingnewtargets pages 98-101): Dorothy Benton. Identifying new targets and drug combinations in neurofibromatosis type 2. ArXiv, 2024. URL: https://doi.org/10.17918/00010718, doi:10.17918/00010718. This article has 1 citations.

  25. (chiranth2023asystematicreview pages 2-4): Shivani Chiranth, Seppo W Langer, Hans Skovgaard Poulsen, and Thomas Urup. A systematic review of targeted therapy for vestibular schwannoma in patients with nf2-related schwannomatosis. Neuro-Oncology Advances, Aug 2023. URL: https://doi.org/10.1093/noajnl/vdad099, doi:10.1093/noajnl/vdad099. This article has 23 citations and is from a peer-reviewed journal.